Page last updated: 2024-08-21

adamantane and Diabetes Mellitus, Adult-Onset

adamantane has been researched along with Diabetes Mellitus, Adult-Onset in 649 studies

Research

Studies (649)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	143 (22.03)	29.6817
2010's	473 (72.88)	24.3611
2020's	33 (5.08)	2.80

Authors

Authors	Studies
Cai, ZJ; Chen, T; Li, N; Lin, WQ; Liu, MB; Zheng, B	1
Gezawa, ID; Salawu, OA; Uloko, AE; Uloko, AT	1
Frías, JP; Hockings, PD; Iqbal, N; Johansson, L; Maaske, J; Suchower, L; Wilding, JPH	1
Poonchuay, N; Uitrakul, S; Wattana, K	1
Fan, L; Ge, Q; Hou, Y; Hu, X; Li, X; Liu, J; Qin, G; Xiao, X; Yang, H; You, Y	1
Chen, W; Li, W; Ni, W; Pan, Y; Sun, Y; Xu, Y; Yang, H	1
Chepulis, L; Keenan, R; Lawrenson, R; Mayo, C; Paul, R	1
Berg, DD; Bhatt, DL; Braunwald, E; Gurmu, Y; Johanson, P; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Sabatine, MS; Scirica, BM; Wilding, JPH; Wiviott, SD	1
Hu, W; Hu, Y; Lv, L; Xing, Y; Ye, S; Zhou, W	1
Qi, X; Tian, J; Zhang, G; Zhang, L; Zhang, Y	1
Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Sun, Z; Wang, X; Wu, T; Xie, C	1
Dicembrini, I; Mannucci, E; Monami, M; Montereggi, C; Nreu, B	2
Cheng, CY; Chiang, CP; Chien, WC; Chung, CH; Hung, CT; Liu, JS; Wang, WM	1
Dronamraju, N; Ekholm, E; Garcia-Sanchez, R; Jabbour, SA; Johnsson, E; Lind, M; Vilsbøll, T	1
Bian, F; Du, J; Fang, H; Li, W; Liang, L; Mu, Y; Shen, L; Wang, X; Xu, C; Xu, F	2
Alenabi, F; Baltzinger, P; Borot, S; Chantrel, F; Cridlig, J; Dorey, F; Ducloux, D; Fleury, D; Guerci, B; Hadjadj, S; Hannedouche, T; Kessler, L; Klein, A; Kunz, K; Meyer, L; Meyer, N; Munch, M; Smagala, A; Verier-Mine, O; Winiszewski, P	1
Dronamraju, N; Frias, JP; Garcia-Sanchez, R; Gonzalez-Galvez, G; Johnsson, E; Maaske, J; Peters, AL; Simonson, DC; Testa, MA	1
Dronamraju, N; Garcia-Sanchez, R; Hockings, PD; Johansson, L; Johnsson, E; Maaske, J; Wilding, JPH	1
Azoulay, L; Bouganim, N; Platt, RW; Rouette, J; Yin, H; Yu, OHY	1
Deng, X; Hu, S; Li, Z; Ma, Y; Wang, Y	1
Li, M; Song, J; Ying, M; Zhuang, Y	1
Chin, KL; Hawley, CM; Jun, M; Lo, C; Oshima, M; Toyama, T; Zoungas, S	1
Feng, X; Gao, G; Gu, Q; Li, Q; Yuan, L; Zhang, Y	1
Orime, K; Terauchi, Y	1
Abdelrahim, MEA; Elberry, AA; Hussein, RRS; Mohamed Rabea, A; Mohsen, M	1
Chen, Y; Dong, B; Hu, J; Wang, J; Wang, Y; Wang, Z	1
Altaha, M; Bello, O; Connelly, KA; Garg, V; Ong, JP; Sandhu, P; Singal, SR; Verma, S; Yan, AT	1
Chiheb, S; Cosson, E; Fysekidis, M; Rezki, A; Valensi, P; Vicaut, E	1
Bhatt, DL; Braunwald, E; Cavallari, I; Im, K; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Scirica, BM; Steg, PG	1
Iftikhar, M; Lu, Y; Zhou, M	1
Cai, JP; Hu, GX; Li, YH; Lin, DD; Lin, QM; Liu, Q; Lu, XR; Ma, YQ; Ou-Yang, QG; Xu, RA	1
Gallo, M; Giaccari, A; Mannucci, E; Monami, M; Montereggi, C; Nreu, B; Ragghianti, B	1
Abdel-Aal, M; Abdel-Ghany, RH; Alsemeh, AE; Ghareib, SA; Sabry, D; Wahba, NS	1
Dey, J	1
Lingvay, I	1
Chu, C; de Vries, F; Kothny, W; Lopez-Leon, S; Schlienger, R; Serban, C; Williams, R	1
Scheen, AJ	11
Acurcio, FA; De Oliveira, GL; Godman, B; Guerra Júnior, AA	1
Chen, J; Leng, F; Li, F; Ling, Y; Lu, Z	1
Chodick, G; Davis, C; Melzer Cohen, C; Shalev, V	1
Bajaj, M; Birnbaum, Y; Perez-Polo, JR; Yang, HC; Ye, Y	1
Hemmingsen, B; Metzendorf, MI; Richter, B; Sonne, DP	1
Eskenazi, D; Fisman, EZ; Goldenberg, I; Goldkorn, R; Klempfner, R; Leor, J; Naftali-Shani, N; Tenenbaum, A; Younis, A	1
Bergenheim, K; Bhatt, DL; Briggs, AH; Hirshberg, B; Johnston, KM; Mosenzon, O; Mukherjee, J; Raz, I; Scirica, BM; Szabo, SM	1
Chen, Q; Huang, L; Kong, L; Wang, J; Wang, Z; Xu, D; Zhang, T; Zhou, X	1
Hua, WC; Li, CM; Liu, Q; Wang, H; Wang, LG	1
Aass, HCD; Åkra, S; Arnesen, H; Byrkjeland, R; Njerve, IU; Seljeflot, I; Solheim, S; Weiss, TW; Øvstebø, R	1
Bombelli, M; Dell'Oro, R; Gamba, P; Grassi, G; Maloberti, A; Mancia, G; Nicoli, F; Villa, P	1
Brouillette, MA; Farahbakhshian, S; Kong, AM; Mukherjee, B; Pendergraft, T; Sheehan, JJ; Smith, DM	1
Kaneko, M; Narukawa, M	1
Atkin, SL; Banach, M; Katsiki, N; Mikhailidis, DP; Pirro, M; Sahebkar, A	1
Hur, KY; Jin, SM; Kim, G; Kim, JH; Lee, MK; Oh, S	1
Chmelik, M; Harreiter, J; Kautzky-Willer, A; Kosi-Trebotic, L; Thomas, A; Trattnig, S	1
Coppenrath, VA; Hydery, T	1
Kadowaki, T; Muto, S; Ouchi, Y; Seino, Y; Shimazaki, R	1
Billger, M; Boulton, DW; Chadwick, KD; Hirshberg, B; Iqbal, N; Pollack, PS; Smith, DM	1
Dou, J; Johnsson, E; Liu, J; Ma, J; Pan, C; Wang, C; Yao, H; Zhao, J	1
Aoki, S; Atsumi, T; Furumoto, T; Inoue, A; Kitao, N; Kurihara, Y; Manda, N; Miya, A; Miyoshi, H; Nakamura, A; Nomoto, H; Ono, K; Tsuchida, K; Yamamoto, C	1
Li, M; Ping, F; Wang, T; Wang, X; Xiao, X; Yu, M; Zhang, Q; Zheng, J	1
Cho, H; Kim, JH; Lee, BW; Lee, WJ; Song, SO; Suh, S	1
Bundhun, PK; Huang, F; Janoo, G; Teeluck, AR	1
Muskiet, MHA; van Baar, MJB; van Raalte, DH	1
Cherney, DZI; Lovblom, LE; Lovshin, JA	1
Attila, T; Mungan, Z; Ünal Kabaoğlu, Z; Vural, M	1
Azuma, K; Goto, H; Ikeda, F; Kanazawa, A; Komiya, K; Masuyama, A; Mita, T; Ogihara, T; Ohmura, C; Osonoi, T; Osonoi, Y; Saito, M; Sato, J; Shimizu, T; Someya, Y; Suzuki, L; Takayanagi, N; Takeno, K; Uzawa, H; Watada, H	1
Chen, Y; Guo, L; Ji, L; Johnsson, E; Li, Q; Li, Y; Liu, X; Lv, X; Ma, J; Shi, Y; Wang, C; Wang, M; Zhao, J	1
Ansari, MT; Baig, MMFA; Khan, GJ; Khan, S; Naeem, MA	1
Bergmark, BA; Bhatt, DL; Bohula, E; Braunwald, E; Cahn, A; Gurmu, Y; Morrow, DA; Mosenzon, O; Raz, I; Scirica, BM; Steg, PG	1
Bhatt, DL; Braunwald, E; Im, K; Kanevsky, E; McGuire, DK; Mosenzon, O; Raz, I; Scirica, BM; Sjöstrand, M; Stahre, C; Steg, PG; Udell, JA	1
Bauer, E; Huang, H; Lang, K; Shetty, S	1
Bowman, B; Cobretti, MR; Grabarczyk, T; Potter, E	1
Kimura, K; Takayanagi, R; Uchida, T; Yamada, Y	1
Hsiao, YC; Hung, YJ; Lee, TI; Lu, YC; Sheu, WH; Tsai, CL; Wang, JS; Yang, WS	1
Chen, H; Del Prato, S; Garcia-Sanchez, R; Hansen, L; Iqbal, N; Johnsson, E; Mathieu, C; Rosenstock, J	1
Liu, W; Tao, T; Wang, Y; Wu, P	1
Bajaj, M; Birnbaum, Y; Yang, HC; Ye, Y	1
Faria-Neto, JR; Lacerda, CS; Marino, EC; Pechmann, LM; Polesel, MG; Vianna, AGD	1
Alexander, GC; Baksh, SN; McAdams-DeMarco, M; Segal, JB	1
Ahmadi, N; Amdur, RL; Domingues, CC; Dore, FJ; Houston, S; Khiyami, A; Kropotova, Y; Kundu, N; Mammadova, A; Rouphael, C; Sen, S; Witkin, L	1
Alghdban, MK; Fischer, A; Forst, T; Heise, T; Kapitza, C; Plum-Mörschel, L; Voswinkel, S; Weber, MM	1
Li, XT; Men, P; Tang, HL; Zhai, SD	1
Chen, K; Mei, Q; Wang, J; Zhuo, T	1
Csomós, K; Cypryk, K; Dronamraju, N; Garcia-Sanchez, R; Jacob, S; Johnsson, E; Kellerer, M; Kurlyandskaya, R; Müller-Wieland, D; Rohwedder, K; Seufert, J; Sjöström, CD; Skripova, D	1
Berlanda, G; Bock, PM; Casali, KR; da Rosa, FM; da Silveira, AD; Fofonka, A; Schaan, BD	1
Jacob, L; Kostev, K; Schokker, E	1
Eriksson, JW; Esterline, R; Johnsson, E; Kamble, PG; Katsogiannos, P; Langkilde, AM; Lundkvist, P; Pereira, MJ	1
Cho, HC; Kim, NH; Kim, SG; Kwak, SH; Lee, J; Lee, YH; Lim, S; Moon, JS; Moon, MK	1
Chen, H; Garcia-Sanchez, R; Mathieu, C; Rosenstock, J; Saraiva, GL	1
Bhatt, DL; Bonaca, MP; Braunwald, E; Gutierrez, JA; Hirshberg, B; Im, K; Mosenzon, O; Raz, I; Scirica, BM; Steg, PG	1
Del Prato, S; Garcia-Sanchez, R; Handelsman, Y; Iqbal, N; Johnsson, E; Kurlyandskaya, R; Mathieu, C; Rosenstock, J	1
Bi, Y; Cheng, J; Gu, T; Li, D; Ma, J; Shao, J; Shi, B; Sun, Z; Xu, L; Zhang, H; Zhang, Q; Zhong, S; Zhu, D; Zhu, L	1
Fan, B; Guo, XL; Li, JJ; Zhang, P; Zheng, ZS	1
Garg, SK; Giordano, D	1
Tuttle, KR	1
García-Sánchez, R; Jacob, S; Johnsson, E; Perl, S; Rosenstock, J	1
Busse, M; Gollop, ND; Marcus, MW; Spanopoulos, D; Tebboth, A; Webb, J	1
Amano, R; Chayama, K; Goto, C; Hashimoto, H; Hidaka, T; Higashi, Y; Hirayama, A; Hiro, T; Kajikawa, M; Kihara, Y; Kishimoto, S; Kurisu, S; Maruhashi, T; Matsui, S; Nakano, Y; Nakashima, A; Noma, K; Sata, M; Shiina, K; Takaeko, Y; Tomiyama, H; Yagi, S; Yamada, H; Yusoff, FM	1
Kaundal, PK; Mokta, JK; Mokta, K; Sahai, AK	1
Bailey, CJ; Del Prato, S; Reyner, D; Saraiva, G; Wei, C	1
Aouidad, I; Crickx, B; Descamps, V; Deschamps, L; Fite, C; Marinho, E	1
Genovese, S; Tedeschi, D	1
Ahrén, B; Foley, JE; Kothny, W; Schweizer, A	1
Blétry, O; Bouilloud, F; Crickx, E; Kahn, JE; Le Beller, C; Marroun, I; Schoindre, Y; Veyrie, C	1
Ben-Hassine, M; Boutarfa, A; Braun, A; Castro, A; Coutant, AL; Crespin, O; Dadji-Faïhun, R; de Miguel, B; Engel, C; Farjot, G; Guillot, E; Güssregen, S; Leger, C; Maniani, K; Monseau, C; Mougenot, C; Mougenot, P; Namane, C; Nicolaï, E; Noah, L; Onofri, B; Pacquet, F; Pascal, C; Philippo, C; Pruniaux, MP; Ragot, JL; Van-Pham, T; Venier, O	1
Bhatt, DL; Braunwald, E; Davidson, J; Frederich, B; Hirshberg, B; Mosenzon, O; Ohman, P; Price, DL; Raz, I; Scirica, BM; Stahre, CI; Steg, PG; Udell, JA	1
Berndt-Zipfel, C; Dworak, M; Forst, T; Löffler, A; Michelson, G; Mitry, M; Pfützner, A	1
Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H	1
García-Ortega, YE; Gómez-Gaitán, EA; González-Ortiz, LJ; González-Ortiz, M; Martínez-Abundis, E; Pérez-Rubio, KG; Robles-Cervantes, JA; Sánchez-Peña, MJ	1
Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Ragonesi, PD	2
Allen, E; Fleming, D; Frederich, R; Karyekar, CS; Ravichandran, S	1
Dengler, TJ; Doesch, AO; Ehlermann, P; Erbel, C; Frankenstein, L; Gleißner, C; Gueler, I; Helmschrott, M; Katus, HA; Mueller, S; Oeing, CU; Ruhparwar, A	1
Ahrén, B; Ekblad, E; Foley, JE; Omar, BA; Vikman, J; Voss, U; Winzell, MS	1
Eriksson, JG; Gallwitz, B; Gause-Nilsson, I; Göke, B; Hellqvist, Å	1
Andrews, C; Azam, M; Barnett, AH; Geransar, P; Hanif, W; Hassanein, M; Kamal, A; Malik, W	1
Charbonnel, B; Dejager, S; Schweizer, A	1
Batra, M; Chaudhuri, A; Dandona, P; Kuhadiya, N; Makdissi, A	1
Morley, JE; Sinclair, A	1
Hoellinger, MJ; Kothny, W; Lukashevich, V; Paldánius, PM; Strain, WD	1
Kožnarová, R	1
Allen, E; Bryzinski, B; Cook, W; Frederich, R; Slater, J	1
Bae, JH; Cho, YM; Jung, HS; Kim, SY; Kim, YG; Oh, TJ; Park, KS	1
Inaba, W; Kamata, K; Mizukami, H; Takahashi, K; Tsuboi, K; Yagihashi, S	2
Forst, T; Foteinos, G; He, YL; Kulmatycki, K; Mattapalli, D; Neelakantham, S; Taylor, A	1
Furihata, K; He, YL; Kulmatycki, K; Mita, S; Saji, T; Sekiguchi, K; Yamaguchi, M	1
Frederich, R; Karyekar, CS; Ravichandran, S	1
Aguilar-Salinas, C; Berglind, N; Fleming, D; Gross, JL; Hissa, M; Ravichandran, S; Rosenstock, J	1
Bell, KF; Curkendall, SM; Juneau, PL; Thomas, N; Weiss, AJ	1
Mahler, RJ	1
Aydogdu, A; Bozoglu, E; Doruk, H; Naharci, MI; Safer, U; Tasci, I; Yilmaz, BF; Yilmaz, G	1
Chatterjee, S	1
Barnett, AH; Charbonnel, B; Donovan, M; Fleming, D; Iqbal, N; Li, J	1
Ji, LN; Li, H; Li, Q; Li, QF; Lu, JM; Pan, CY; Peng, YD; Tian, HM; Wang, L; Wang, XL; Yao, C; Zhang, RY; Zhao, ZG	1
Bader, G; Barnett, AH; Brath, H; Conget, I; de Castro, JJ; Göke, R; Kothny, W; Márquez Rodriguez, E; Mathieu, C; Nilsson, PM; Pagkalos, E; Penfornis, A; Schaper, NC; Wangnoo, SK	1
Bhatt, DL; Braunwald, E; Cavender, MA; Davidson, J; Desai, NR; Frederich, R; Hirshberg, B; Hoffman, EB; Leiter, LA; McGuire, DK; Mosenzon, O; Ohman, P; Ray, KK; Raz, I; Scirica, BM; Steg, PG; Udell, JA; Wiviott, SD	1
Al-Arouj, M; Chawla, MS; Ditommaso, S; Hassoun, AA; Hristoskova, S; Kadwa, MY; Medlej, R; Pathan, MF; Shaltout, I	1
Kosaka, T; Kuwahara, Y; Nakamura, K; Otsuki, H; Shimomura, F; Tsukamoto, T	1
Lim, GB	1
Greenhill, C	1
Buikema, H; Deelman, LE; Dokkum, RP; Henning, RH; Landheer, SW; Vavrinec, P; Wang, Y	1
Ahmed, I	1
Ishibashi, Y; Maeda, S; Matsui, T; Nakashima, S; Nishino, Y; Ojima, A; Yamagishi, S; Yamakawa, R; Yoshida, Y	1
Abe, H; Fujitani, Y; Hara, A; Ishibashi, K; Kanazawa, A; Kawamori, R; Komiya, K; Ogihara, T; Tamaki, M; Uchida, T; Watada, H	1
Mitka, M	1
Aleksandrov, AA; Chernova, TO; Dedov, II; Il'in, AV; Shestakova, MV; Shmushkovich, IA; Suhareva, OIu	1
Araki, E; Goto, R; Igata, M; Kawasaki, S; Kawashima, J; Kitano, S; Kondo, T; Matsumura, T; Matsuyama, R; Miyagawa, K; Motoshima, H; Ono, K	1
Araga, M; Del Prato, S; Kothny, W; Lukashevich, V	1
Brook, D; Fisher, SA; Kalra, S; Montanaro, M; Monyak, J; Moses, RG; Sockler, J; Visvanathan, J	1
Hardy, G	1
Smahelová, A; Spinar, J	1
Antlanger, M; Döller, D; Haidinger, M; Hecking, M; Kopecky, C; Kovarik, JJ; Pacini, G; Pleiner, J; Säemann, MD; Stemer, G; Werzowa, J	1
Anz, D; Bourquin, C; Endres, S; Haubner, S; Kruger, S; Rapp, M	1
Bader, G; Dworak, M; Göke, R; Gruenberger, JB	1
Brada, M; Dohnalová, L; Edelsberger, T; Gerle, J; Haluzík, M; Houdová, J; Veselá, V	1
Donovan, M; Edelberg, H; Hirshberg, B; Iqbal, N; Parker, A	1
Minervini, G; Mintz, ML	1
Boyd, S; deSchoolmeester, J; Dossetter, AG; Goldberg, FW; Groombridge, SD; Gutierrez, PM; Kemmitt, PD; Robb, GR; Scott, JS; Sjögren, T; Swales, JG; Turnbull, AV; Wild, MJ	1
Bramlage, P; Friedrich, S; Harazny, JM; Kistner, I; Ott, C; Raff, U; Schmidt, S; Schmieder, RE	1
Montori, VM; Morey-Vargas, OL	1
Davidson, JA	1
Honka, M	1
Bhatt, DL; Braunwald, E; Scirica, BM	1
Standl, E	1
Derosa, G; Maffioli, P	2
Gresnigt, MS; Netea, MG; Smits, P; Tack, CJ; van Poppel, PC	1
Donovan, M; Frederich, R; Hirshberg, B; Iqbal, N; Parker, A	1
Aravind, SR	1
Dhindsa, S; Jialal, I	1
Tibaldi, JM	1
Davis, SN; Lamos, EM; Stein, SA	1
Ahrén, B; Farngren, J; Foley, JE; Persson, M; Schweizer, A	1
Mullard, A	1
Abdul-Ghani, M; Cakirca, M; Camli, AA; Cikrikcioglu, MA; Erkoc, R; Hursitoglu, M; Kanat, M; Karatoprak, C; Kiskac, M; Soysal, P; Zorlu, M	1
Dunn, A	1
Keating, GM	2
Dimmitt, SB; Doggrell, SA	1
Davis, TM	1
Calado, F; Carvalho, D; Gruenberger, JB; Johal, S; Ong, SH; Silva-Nunes, J; Viana, R; Viriato, D	1
Athyros, VG; Elisaf, MS; Filippatos, TD	1
Burlina, S; Chilelli, NC; Lapolla, A; Sartore, G	1
Dicembrini, I; Mannucci, E; Monami, M	1
Górska, J; Rokicka, D; Sędek, Ł; Strojek, K; Szczepański, T; Szymborska-Kajanek, A; Wróbel, M	1
Daci, E; Hoste, J; Mathieu, C	1
Kothny, W; Kozlovski, P; Li, Y; Lukashevich, V; Lv, X; Ma, J; Sun, F; Wang, W; Woloschak, M; Xing, X; Yang, W; Yuan, G	1
Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D	2
Bramlage, P; Forst, T	1
Ding, M; Li, CJ; Liu, XJ; Yu, DM; Yu, P; Yu, Q; Zhang, QM	1
Del Prato, S; Foley, JE; Kothny, W; Kozlovski, P; Matthews, DR; Paldánius, PM; Stumvoll, M	1
Almada, J; Angel, ID; Márquez-Rodríguez, E; Mendivil, CO; Paz, G; Rodríguez, C; Szyskowsky, O	1
Avogaro, A; Dardano, A; de Kreutzenberg, SV; Del Prato, S	1
Albiero, M; Avogaro, A; Cappellari, R; Fadini, GP; Menegazzo, L; Poncina, N	1
Bhatt, DL; Buskila, A; Greenberger, N; Hirshberg, B; Im, K; Iqbal, N; Lerch, MM; Mosenzon, O; Raz, I; Scirica, BM; Stahre, C; Umez-Eronini, A	1
Abdallah, K; Hassanein, M; Schweizer, A	1
Lee, CF; Sun, MS; Tai, YK	1
Ahrén, B; Liehua, L; Marchetti, P; Omar, BA; Seino, Y; Yamada, Y	1
Hirshberg, B; Iqbal, N; Lu, J; Sjöstrand, M	1
Chen, H; Chen, R; Liu, Y; Sun, J; Zhang, Z	1
Gallwitz, B; Nitschmann, S	1
Navarro-Artieda, R; Sicras-Mainar, A	1
Choi, SA; Jang, JY; Jung, HS; Kim, HC; Kim, JH; Kim, MJ; Kim, SW; Lee, HM; Lee, KB; Ohn, JH; Park, KS; Yoon, JW	1
Bossi, AC; Candido, R; Cioffi, G; Di Lenarda, A	1
Chiamvimonvat, N; Despa, F; Despa, S; Dong, H; Hammock, BD; Harris, TR; Li, N; Margulies, KB; Sharma, S; Taegtmeyer, H	1
Belle-van Meerkerk, G; Beulens, JW; Biesma, DH; de Ranitz-Greven, WL; de Valk, HW; Hoeks, LB	1
Fonarow, GC	1
Bhatt, DL; Braunwald, E; Cavender, MA; Davidson, J; Frederich, R; Hirshberg, B; Im, K; Jarolim, P; Lewis, BS; McGuire, DK; Morrow, DA; Mosenzon, O; Pollack, PS; Raz, I; Scirica, BM; Steg, PG; Udell, JA; Umez-Eronini, AA	1
Dongre, N; Groop, PH; Kothny, W	1
Chen, LM; Guo, H; Guo, X; Kong, Y; Li, CJ; Li, DQ; Liu, DM; Wu, YJ; Yang, Y; Zhang, J	1
Okamoto, A; Sanada, H; Yokokawa, H	1
Allen, E; Iqbal, N; Öhman, P	1
Birdsey, N; Keller, AC; Klemm, DJ; Knaub, LA; Miller, MW; Reusch, JE	1
Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP	1
Deng, H; Li, Y; Lin, K; Wu, W; Xu, L; Zhang, W; Zhi, X	1
Cook, W; Hansen, L; Hirshberg, B; Iqbal, N; Li, Y; Rosenstock, J; Zee, P	1
Casali, KR; Fofonka, A; Ribeiro, JP; Schaan, BD	1
Bryzinski, B; Cook, W; Hirshberg, B; Minervini, G	1
Bader, G; Blüher, M; Foley, JE; Schweizer, A	1
Ahn, SK; Byun, SY; Hong, SP; Nam, KY; Shin, YJ	1
Clifton, P	1
Goundan, PN; Mantzoros, CS; Underwood, P	1
Dütting, ED; Eschenbach, P; Göke, R	1
Curkendall, SM; Farr, AM; Johnston, SS; Kalsekar, I; Sheehan, JJ; Smith, DM	1
Bhatt, DL; Braunwald, E; Cavender, MA; Corbalan, R; Davidson, JA; Frederich, R; He, P; Hirshberg, B; Im, K; Leiter, LA; McGuire, DK; Mosenzon, O; Nicolau, JC; Raz, I; Scirica, BM; Steg, PG; Udell, JA; Umez-Eronini, AA	1
Basiak, M; Drożdż, M; Okopień, B; Stęposz, A; Strózik, A	1
Toth, PP	1
Bialek, C; Brath, H; Gingl, E; Prager, R; Ratzinger, M; Resl, M	1
Abou Jaoude, E; Al-Arouj, M; DiTommaso, S; Fawwad, A; Latif, ZA; Orabi, A; Rosales, R; Shah, P; Vaz, J	1
Dangi-Garimella, S	1
Hirayama, A; Nagao, K; Takahashi, A; Tani, S	1
Bhatt, DL; Braunwald, E; Cahn, A; Hirshberg, B; Im, K; Jermendy, G; Leibowitz, G; Mosenzon, O; Raz, I; Scirica, BM; Sendon, JL; Sheu, WH; Wei, C	1
Al-Mrabeh, A; Foley, JE; Hollingsworth, KG; Macauley, M; Schweizer, A; Smith, FE; Taylor, R; Thelwall, PE	1
Akin, F; Ar, IB; Ayvaz, G; Dokmetas, HS; Keskin, L; Tasan, E; Uren, E	1
Abdul-Ghani, M	1
Al-Saber, FA; Bader, G; Haddad, J; Ibrahim, M; Jallo, MK; Saab, C; Steitieh, H	1
Bhatt, DL; Bonnici, F; Braunwald, E; Cahn, A; Frederich, R; Hirshberg, B; Kumar, KM; Leiter, LA; Mosenzon, O; Raz, I; Scirica, BM; Smahelova, A; Stahre, C; Teoh, H	1
Durán-Garcia, S; Hanefeld, M; Hardy, E; Langslet, G; Malvolti, E; Niskanen, L; Östgren, CJ; Schernthaner, G	1
Dicembrini, I; Mannucci, E	1
Brady, EM; Dales, J; Davies, MJ; Gray, LJ; Hanif, W; Khunti, K	1
Kobayashi, M; Nakajima, K; Niwa, T; Shimodaira, M	1
Fawwad, A; Hasan, MI; Hussain, S; Khan, MA; Khan, MI; Kumar, K; Mahar, SA; Maheshwary, N; Siddiqi, A	1
Chen, YM; Lin, S; Lu, HY; Mu, PW; Shu, J; Wang, MM; Xie, RY; Zeng, LY; Zhang, YJ	1
Burciu, C; Koska, J; Reaven, P; Sands, M	1
Godoy J, G; Gutiérrez, V; Montecinos, M; Yenes, A	1
Dworak, M; Forst, T; Koch, C	1
Nishikido, T; Node, K; Ohira, H; Oyama, J	1
Bhullar, H; Carbonari, DM; Cardillo, S; Esposito, DB; Gallagher, AM; Haynes, K; Hennessy, S; Holick, CN; Lo Re, V; Newcomb, CW; Nezamzadeh, MS; Roy, JA; Saine, ME; Strom, BL	1
Delivanis, DA; Montori, VM	1
Kothny, W; Li, L; Lukashevich, V; Lv, X; Ma, J; Ning, G; Wang, W; Woloschak, M; Yang, M	1
Deng, J; Dong, H; Gu, S; Mu, Y; Shi, L	1
Baruah, MP; Gupta, A; Gupta, Y; Kalra, S	1
Choi, SH; Hong, AR; Hwangbo, Y; Jang, HC; Kim, KM; Ku, EJ; Lee, J; Lim, S; Moon, JH	1
Foley, JE; Kothny, W; Lukashevich, V; Rendell, MS; Schweizer, A	1
Asahara, S; Bartolome, A; Inoue, H; Kanno, A; Kawamoto, T; Kido, Y; Koyanagi-Kimura, M; Matsuda, T; Matsuura, Y; Mieda, Y; Ogawa, W; Seino, S; Shimizu, S; Suzuki, E; Takahashi, H; Takai, T; Yokoi, N	1
Hulshof, TA; Luijendijk, HJ	1
Federici, M; Kappel, BA; Marx, N	1
Cosenso-Martin, LN; Giollo-Junior, LT; Vilela-Martin, JF	1
Dejager, S; Deschaseaux, C; Detournay, B; Halimi, S; Robert, J	1
Chen, H; Cook, W; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Li, D; Mathieu, C; Ranetti, AE	1
Del Prato, S; Evans, M; Kothny, W; Lukashevich, V; McInnes, G; Schweizer, A; Shao, Q; Stumvoll, M	1
Ishikawa, S; Kouzu, H; Kuno, A; Miki, T; Miura, T; Murase, H; Nishizawa, K; Ogasawara, M; Tanno, M; Tobisawa, T; Yano, T	1
Muskiet, MH; Tonneijck, L; van Raalte, DH	1
Bhatt, DL; Braunwald, E; Cavender, MA; Davidson, J; Frederich, R; Hirshberg, B; Im, K; Jarolim, P; Lewis, BS; McGuire, DK; Morrow, DA; Mosenzon, O; Pollack, PS; Raz, I; Scirica, BM; Steg, G; Udell, JA; Umez-Eronini, AA	1
Fan, X; Fan, Y; Li, X; Ren, F; Ren, G; Shen, C; Shen, J; Song, Y; Yang, J; Zhang, N; Zhang, Y; Zheng, H	1
Catrinoiu, D; Celiński, A; Chen, H; Cook, W; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Matthaei, S	1
Bhatt, DL; Cahn, A; Davidson, J; Hirshberg, B; Mosenzon, O; Raz, I; Rozenberg, A; Scirica, BM; Stahre, C; Strojek, K; Wei, C; Yanuv, I	1
Hirshberg, B; Katz, A	1
Stephens, JW; Williams, DM	1
Dhillon, S	1
Bhatt, DL; Cahn, A; Mosenzon, O; Raz, I; Scirica, BM	1
Apaijai, N; Chattipakorn, N; Chattipakorn, SC	1
Alvarsson, M; Bhatt, DL; Cahn, A; Hirshberg, B; Hoekstra, JB; Im, K; Leiter, LA; Mosenzon, O; Raz, I; Scirica, BM; Stahre, CA; Teoh, H	1
Duranti, E; Natali, A; Rossi, C; Solini, A; Taddei, S; Virdis, A	1
Bhatt, DL; Braunwald, E; Cahn, A; Cavender, MA; Davidson, J; Hirshberg, B; Im, K; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Scirica, BM; Steg, PG	1
Jain, R	1
D'Angelo, A; Derosa, G; Franzetti, I; Maffioli, P; Querci, F	1
Špinar, J; Špinarová, L; Vítovec, J	1
Gu, W; Li, Y; Liang, L; Ning, G; Piao, C; Tan, X; Tian, J; Wang, S; Wang, W; Wang, Y; Wu, Y; Xin, X; Yang, G; Yin, J	1
Athanasiadou, E; Bekiari, E; Boura, P; Karagiannis, T; Liakos, A; Mainou, M; Papatheodorou, K; Rika, M; Rizava, C; Tsapas, A	1
Brouillette, M; Farr, AM; Johnston, SS; Kalsekar, I; Sheehan, JJ; Smith, DM	1
Cappell, K; Cole, AL; Fowler, R; Fu, AZ; Ghannam, A; Johnston, SS; Kalsekar, I; Riehle, E; Sheehan, J; Tsai, K	1
Baker, WL; White, WB	1
Borg, M; Bound, MJ; Deacon, CF; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Wu, T; Zhang, X	1
Bhosekar, V; Foley, JE; Kawamori, R	1
Béni, S; Fejős, I; Hu, W; Kazsoki, A; Sohajda, T; Szente, L; Zhou, W	1
Anderson, R; Hayes, J; Stephens, JW	1
Cahn, A; Cernea, S; Raz, I	1
Jing, W; Shunyou, D; Xiaochun, H; Xiaoyan, C; Yingyu, F; Yuyu, T	1
Geissel, W	1
Bonora, E; Bryzinski, B; Cook, W; Hirshberg, B	1
Jermendy, G	3
Antonazzo, IC; De Ponti, F; Koci, A; Marchesini, G; Poluzzi, E; Raschi, E	1
Balakrishnan, S; Brown, NJ; Fireman, BH; Graham, DJ; Griffin, MR; Hamilton, J; Hampp, C; Iyer, A; Lendle, S; Nathwani, N; Pimentel, M; Pucino, F; Reichman, ME; Rucker, M; Toh, S	1
Amblee, A; Fogelfeld, L; Lious, D	1
Bugáňová, M; Haluzík, M; Holubová, M; Kaválková, P; Kuneš, J; Kuzma, M; Maletínská, L; Pelantová, H; Šedivá, B; Sýkora, D; Železná, B; Zemenová, J	1
Babazono, T; Hanai, K; Uchigata, Y; Yoshida, N	1
Broschag, M; Deacon, CF; Foley, J; He, YL; Holst, JJ; Kind, J; Kjems, L; Köthe, LD; Nauck, MA	1
Korabecny, J; Kuca, K; Nepovimova, E; Soukup, O; Spilovska, K; Windisch, M; Zemek, F	1
Bhatt, DL; Braunwald, E; Cahn, A; Hirshberg, B; Im, K; Iqbal, N; Kanevsky, E; Leibowitz, G; Mosenzon, O; Raz, I; Rozenberg, A; Scirica, BM; Sjostrand, M; Stahre, C; Yanuv, I	1
Boulton, DW	1
Baranov, O; Deacon, CF; Holst, JJ; Kahle, M; Nauck, MA	1
Charbonnel, B; Dejager, S; Fiquet, B; Gautier, JF; Monguillon, P; Valensi, P; Verier-Mine, O	1
Abiru, N; Ando, T; Horie, I; Kawakami, A; Shigeno, R	1
Abe, M; Higuchi, T; Kikuchi, F; Moriuchi, M; Nagura, C; Okada, K; Okamura, M; Takashima, H; Tei, R; Tomita, H	1
Atsumi, T; Cho, KY; Dan-Noura, M; Koyanagawa, N; Miyoshi, H; Nakamura, A; Ono, K; Takano, Y; Yamamoto, K	1
Brath, H; Gawai, A; Mathieu, C; Paldánius, PM; Phadke, U; Prasanna Kumar, KM	1
Bader, G; Brath, H; Kolaczynski, WM; Nilsson, PM; Paldánius, PM	1
Chen, H; Garcia-Sanchez, R; González González, JG; Hansen, L; Herrera Marmolejo, M; Iqbal, N; Johnsson, E; Mathieu, C	1
Emoto, N; Kato, K; Okajima, F; Sugihara, H	1
Aggarwal, N; Chen, H; Chin, A; Garcia-Hernandez, P; Hansen, L; Iqbal, N; Johnsson, E; Matthaei, S	1
Ji, LN; Li, H; Li, Q; Li, QF; Lu, JM; Pan, CY; Peng, YD; Tian, HM; Wang, BH; Wang, L; Yao, C; Zhao, ZG; Zhu, DL	1
Cahn, A; Raz, I; Schernthaner, G	1
Ersoy-Evans, S; Gököz, O; Gönül, M; Keseroglu, HO; Taş-Aygar, G	1
Bingham-Gardiner, P; Bolodeoku, J; Hassan, SW; Lee, S; Scowcroft, A; Spencer, W; Tebboth, A	1
Cha, BS; Han, E; Kang, ES; Kim, BS; Kim, CS; Lee, BW; Lee, YH; Nam, JY; Park, SH	1
Furukawa, T; Kamoi, K; Kaneko, K; Kaneko, M; Maruyama, R; Ohara, N; Sato, K; Tanaka, J	1
El Sarha, A; Refaat, R; Sakr, A; Salama, M	1
Jütte, H; Meier, J; Montanya, E; Nauck, M; Schmidt, W; Tannapfel, A; Ueberberg, S; Uhl, W	1
Evans, M; Foley, JE; Schweizer, A	1
Cho, YM; Jang, HC; Jung, HS; Kim, SY; Kwak, S; Park, KS	1
Bound, MJ; Deacon, CF; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Trahair, LG; Wu, T; Zhang, X	1
Mudher Mikhael, E	1
Raz, I; Tkáč, I	1
Hernández, C; Simó, R	1
Al-Arouj, M; Hassoun, AA; Ibrahim, M	1
Jiang, LL; Li, FF; Ma, JH; Su, XF; Wu, JD; Yan, RN; Ye, L; Zhang, DF; Zhou, PH; Zhu, HH	1
Cook, W; Hirshberg, B; Ohman, P; Perl, S; Wei, C	1
Arao, T; Hajime, M; Kuno, F; Kurozumi, A; Mine, S; Miyazaki, M; Mori, H; Narisawa, M; Okada, Y; Sonoda, S; Sugai, K; Tanaka, K; Tanaka, Y; Torimoto, K	1
Mannucci, E; Monami, M	1
Carlsson, B; Chen, H; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Johnsson, E	1
Dong, H; Gu, S; Hu, X; Yu, D; Zeng, Y	1
Liu, G; Liu, X; Men, P; Wang, Y; Zhai, S	1
Kanazawa, I; Kiyohara, N; Koike, S; Notsu, M; Sasaki, M; Sugimoto, T; Tada, Y; Tanaka, KI; Tanaka, S; Yamane, Y; Yamauchi, M	1
Fonseca, M; Kothny, W; Kozlovski, P; Lukashevich, V; Mohan, V; Odawara, M; Paldánius, PM	1
Eom, YS; Gwon, AR; Kim, BJ; Kim, JY; Kim, KW; Kim, YS; Kwak, KM; Lee, K; Lee, S; Park, IB; Yu, SH	1
Garnock-Jones, KP	1
Bhatt, DL; Cahn, A; Hirshberg, B; Im, K; Iqbal, N; Kanevsky, E; Leibowitz, G; Mosenzon, O; Raz, I; Rozenberg, A; Stahre, C; Yanuv, I	1
Chen, YW; Fu, CP; Lee, CL; Lee, IT; Lin, SY; Sheu, WH; Song, YM; Wang, JS	1
Bound, MJ; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Sun, Z; Trahair, LG; Wu, H; Wu, T; Zhang, X	1
Atsumi, T; Cho, KY; Kameda, H; Kimachi, K; Kondo, T; Miyoshi, H; Nagai, S; Nakamura, A; Nomoto, H	1
Abdallah, DM; Al-Shorbagy, MY; Aldakinah, AA; El-Abhar, HS	1
Álvarez-Guisasola, F; Cebrián Cuenca, AM; Consuegra-Sánchez, L; Navarro Pérez, J; Núñez Villota, J; Orozco Beltrán, D	1
Rakha, S; Shelbaya, S	1
Bailey, CJ; Flatt, PR; Green, BD	2
Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S	1
Ahrén, B	7
Pei, Z	1
Gadsby, R	1
Doupis, J; Veves, A	1
Calle Pascual, A; Dejager, S; Foley, J; Göke, B; Hershon, K; Kerr, D; Schweizer, A; Shao, Q	1
Cheng, Q; de Gasparo, M; Law, PK; Leung, PS	1
Balez, S; Bullock, J; Dole, WP; He, YL; Jarugula, V; Ligueros-Saylan, M; Riviere, GJ; Schwartz, S; Serra, D; Wang, Y	1
Davidson, JA; Gross, JL; Parente, EB	1
Dejager, S; Foley, J; Halimi, S; Minic, B; Schweizer, A	1
Faust, M; Matthes, J	1
Fonseca, VA; John-Kalarickal, J; Wani, JH	1
Bock, G; Camilleri, M; Cobelli, C; Dalla Man, C; Foley, JE; Giesler, PD; Ligueros Saylan, M; Rizza, RA; Serra, DB; Toffolo, G; Vella, A	1
D'Alessio, DA; Denney, AM; Dunning, BE; Foley, JE; He, Y; Hermiller, LM; Martin, JM; Pratley, RE; Prigeon, RL; Saylan, ML; Tharp, WG	1
Croxtall, JD; Keam, SJ	1
Bosi, E; Lucotti, P; Monti, L; Piatti, PM; Setola, E	1
Gallwitz, B	3
Bandeira-Echtler, E; Bergerhoff, K; Lerch, C; Richter, B	1
Gwaltney, SL	1
Boehnke, J; Boschmann, M; Budziarek, P; Dobberstein, K; Engeli, S; Foley, JE; He, Y; Jordan, J; Luft, FC; Strauss, A; Sweep, FC	1
Abe, N; Kato, M; Kikuchi, M; Mimori, N; Tachibana, H; Terao, S	1
Ahrén, B; Byiers, S; Dejager, S; Ferrannini, E; Fonseca, V; Matthews, D; Shao, Q; Zinman, B	1
Gupta, R; Pal, M; Parsa, KV; Singh, SK; Tokala, RK; Walunj, SS	1
Ahrén, B; Dejager, S; Dunning, BE; Foley, JE; Nilsson, PM; Persson, M; Schweizer, A	1
Siddiqui, NI	1
Goodman, M; Penman, J; Thurston, H	1
Argyrakopoulou, G; Doupis, J	1
Nicolucci, A; Rossi, MC	1
Barnett, AH; Piya, MK; Tahrani, AA	2
Bosi, E; Dotta, F; Goodman, M; Jia, Y	1
Mikhail, N	3
Degrande, E; Mathieu, C	1
Dole, WP; He, YL; Herron, J; Ligueros-Saylan, M; Picard, F; Sabo, R; Wang, Y	1
Maldonado-Lutomirsky, M; Niggli, M; Rosenstock, J	1
Scherbaum, WA	1
Mathieu, C	1
Barnett, AH	1
Paquot, N; Scheen, AJ	1
Deacon, CF; Holst, JJ	1
Bosi, E; Dejager, S; Schweizer, A	1
Chen, RS; DeFronzo, RA; Garber, AJ; Hissa, MN; Luiz Gross, J; Ravichandran, S; Yuyan Duan, R	1
Bolli, G; Colin, L; Dotta, F; Goodman, M; Minic, B	1
Allen, E; Chen, R; Jadzinsky, M; Paz-Pacheco, E; Pfützner, A; Xu, Z	1
Apanovitch, A; Chacra, AR; Chen, R; List, J; Ravichandran, S; Tan, GH	1
Banerji, MA; Baron, M; Blonde, L; Braceras, R; Dagogo-Jack, S; Marcellari, A; Pratley, RE; Purkayastha, D	1
Aguilar-Salinas, C; Chen, R; Klein, E; List, J; Nepal, S; Rosenstock, J	1
Bravis, V; Devendra, D; Gohel, B; Hassanein, M; Hui, E; Mehar, S; Salih, S	1
Foley, JE; Sreenan, S	1
Traynor, K	1
Gallwitz, B; Thornberry, NA	1
Bell, PM; Duffy, NA; Flatt, PR; Green, BD; Lindsay, JR; McKillop, AM; O'Harte, FP; Patterson, S	1
Curtiss, FR; Fairman, KA	1
Bode, BW	1
Allen, E; Chen, R; Hollander, P; Li, J	1
Banerjee, M; Soran, H; Younis, N	1
Colucci, RA; Schwartz, FL; Shubrook, JH	1
Barnett, AH; Palalau, AI; Piya, MK; Tahrani, AA	1
Freeman, JS	1
Bodvarsdottir, TB; Gotfredsen, CF; Heller, RS; Karlsen, AE; Knudsen, LB; Vedtofte, L	1
Ahrén, B; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, VA; Matthews, DR; Zinman, B	1
LaSalle, JR	1
Bilo, HJ; Goudswaard, AN; Houweling, ST; Kleefstra, N; Kooy, A; van Hateren, KJ; Verhoeven, S	1
Cefalu, WT	1
Billiones, R	1
Aggarwal, S; Bhardwaj, TR; Haksar, D; Kumar, M; Malla, P; Thareja, S	1
Dejager, S; Halimi, S; Raccah, D; Schweizer, A	1
Borja-Hart, NL; Whalen, KL	1
Alexander, JH; Berglind, N; Chen, R; Donovan, M; Fiedorek, FT; Frederich, R; Harris, S; Mahaffey, KW; Wolf, R	1
Guerci, B; Halter, C	1
Couturier, A; Dejager, S; Foley, JE; Kothny, W; Ligueros-Saylan, M; Schweizer, A	1
Couturier, A; Foley, JE; Kothny, W; Ligueros-Saylan, M; Schweizer, A	1
Filozof, C; Gautier, JF	1
Couturier, A; Goodman, M; Haneda, M; Inaba, Y; Kikuchi, M; Koya, D; Mimori, N; Onishi, Y; Tobe, K	1
Unger, J	1
Ciccarelli, L; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Mereu, R; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA	1
Kuritzky, L	1
Valiquette, G	1
Iwamoto, Y; Kashiwagi, A; Mimori, N; Suzuki, M; Tachibana, H; Terao, S; Yamada, N	1
Fakhoury, WK; Lereun, C; Wright, D	1
Dole, WP; Foley, J; He, YL; Ligueros-Saylan, M; Schwartz, SL; Valencia, J; Zhang, Y	1
Svec, F	1
Clar, C; Cummins, E; Marien, M; Philip, S; Richter, B; Royle, P; Waugh, N	1
Ahren, B; Couturier, A; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, V; Matthews, DR; Zinman, B	1
Banerji, MA; Francis, BH; Purkayastha, D	1
Gerich, J	1
Moreira, RO; Nascimento, TS; Zagury, L; Zagury, RL	1
Foley, JE; Jordan, J	1
Berglind, N; Chen, R; Neutel, J; Ravichandran, S; Raz, I; Stenlöf, K	1
Garber, AJ	1
Campbell, RK; Neumiller, JJ	1
Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME	5
Charpentier, G; Gause-Nilsson, I; Hellqvist, A; Ostgren, CJ; Scheen, AJ	1
Eriksson, J; Gallwitz, B; Gause-Nilsson, I; Göke, B; Hellqvist, A	1
He, YL; Ito, H; Sekiguchi, K; Terao, S; Yamaguchi, M	1
Ito, H; Mimori, N; Sekiguchi, K; Wajima, T; Yamaguchi, M	1
Dejager, S; Foley, JE; Kothny, W; Schweizer, A; Shao, Q	1
Anandan, SK; Chen, D; Gless, RD; MacIntyre, DE; Rubanyi, GM; Vincelette, J; Wang, YX; Webb, HK; Zhang, LN	1
Ahrén, B; Bosi, E; Foley, JE	1
Deacon, CF; Foley, JE; Holst, JJ; Köthe, LD; Nauck, MA; Schweizer, A; Vardarli, I	1
Boudes, P; Viereck, C	1
Jellinger, PS	1
Matsui, T; Nishino, Y; Takeuchi, M; Yamagishi, S	1
Chacra, A; Doucet, J; Harris, S; Lu, J; Maheux, P; Rosenstock, J	1
Boulton, DW; Brenner, E; Handschuh del Corral, M; Komoroski, B; Kornhauser, D; Li, L; Patel, CG; Vachharajani, N	1
Gause-Nilsson, I; Haller, H; Nowicki, M; Rychlik, I; Suchower, L; Warren, ML	1
Allen, E; Chen, R; Frederich, R; Paz-Pacheco, E; Pfützner, A	1
Boulton, DW; Castaneda, L; Frevert, EU; Kornhauser, DM; Li, L; Patel, CG; Tang, A; Vachharajani, NN	1
Codd, R; Liao, V; Lifa, T; Liu, J; Obando, D	1
Dejager, S; Foley, JE; Kothny, W; Schweizer, A	1
Bourdel-Marchasson, I; Dejager, S; Schweizer, A	1
Seino, Y	1
Ahrén, B; Dejager, S; Dunning, BE; Foley, JE; Schweizer, A; Villhauer, EB	1
Bunck, MC; Diamant, M; Eekhoff, EM; Foley, JE; Heine, RJ; Möller-Goede, DL; Nijpels, G; Poelma, M; Schweizer, A	1
Chen, RS; Deacon, CF; Duan, RY; Henry, RR; Holst, JJ; List, JF; Mudaliar, SR; Schwartz, SL; Smith, SR	1
Allen, E; Chen, R; Frederich, R; Hollander, PL; Li, J	1
Chacra, AR; Chen, R; List, J; Ravichandran, S; Tan, GH	1
Andrews, C; Barnett, A; Geransar, P; Hanif, W; Hassanein, M; Kamal, A; Lister, N; Malik, W	1
Avogaro, A; de Kreutzenberg, SV; Fadini, GP; Gjini, R	1
Iwamoto, Y	1
Schneider, SH; Stamataros, G	1
Allen, E; Chen, R; Donovan, M; Fleming, D; Karyekar, C; Ravichandran, S	1
Groop, PH; Kothny, W; Lukashevich, V; Schweizer, A; Shao, Q	1
Kalra, S	1
Gautier, JF; Sauvanet, JP	1
Albuquerque, JL; Alves, Gdos S; Canadas, V; Cunha, RA; Ferreira, VM; Gusmão, A; Ibiapina, GR; Lima, JG; Montenegro, L; Nóbrega, LH; Pontes, L; Pontes, S; Vilar, L	1
Netea, MG; Smits, P; Tack, CJ; van Poppel, PC	1
Gonzalvo, JD; Kania, DS; Weber, ZA	1
Fan, L; Gruenberger, JB; Kantor, E; Signorovitch, JE; Swallow, E; Wu, EQ	1
Gause-Nilsson, I; Pan, CY; Tou, C; Yang, W; Zhao, J	2
Brock, M; McFarland, MS; Ryals, C	2
Barboza, J; Sando, KR; Taylor, J; Willis, C	1
Aerts, JM; Aten, J; Bietrix, FM; Bijl, N; Boot, RG; Dekker, N; Groen, AK; Groener, J; Langeveld, M; Lombardo, E; Ottenhoff, R; Overkleeft, HS; Serlie, M; van Eijk, M; van Roomen, C; Wennekes, T	1
Abe, M; Higuchi, T; Ito, M; Kikuchi, F; Maruyama, N; Okada, K; Sasaki, H; Soma, M; Tsuchida, M	1
Gause-Nilsson, I; Haller, H; Nowicki, M; Rychlik, I; Schützer, KM; Suchower, L; Warren, M	1
Chen, SY; Golla, R; Gordon, DA; Harper, T; He, B; Kirby, M; Li, YX; Nayeem, A; Robl, JA; Seethala, R; Sleczka, BG; Wang, M; Ye, XY	1
Bergenheim, K; Granström, O; Henriksson, M; McEwan, P; Sennfält, K	1
Bunck, MC; Diamant, M; Eekhoff, EM; Foley, JE; Heine, RJ; Nijpels, G; Poelma, M; Schweizer, A	1
Czupryniak, L; Grzeszczak, W; Kolasa, K; Lomon, ID; McEwan, P; Sciborski, C	1
Bhatt, DL; Braunwald, E; Chen, R; Davidson, J; Hirshberg, B; Ohman, P; Price, DL; Raz, I; Scirica, BM; Steg, PG; Udell, J	1
Gerrald, KR; Jonas, DE; Runge, T; Van Scoyoc, E; Wines, RC	1
Schwartz, SL	1
Barbee, T; Correa, I; Fredrickson, J; Gibbs, JP; Gibbs, MA; Lin, SL; Smith, B	1
Cai, L; Cai, Y; Liu, P; Lu, ZJ; Zhang, Y	1
Fonseca, V; Hirshberg, B; Karyekar, C; Zhu, T	1
Yang, LP	1
Cobble, ME; Frederich, R	1
Bergenheim, K; Duprat-Lomon, I; Erhardt, W; McEwan, P	1
Barnett, AH; Charbonnel, B; Chen, R; Donovan, M; Fleming, D	1
He, YL	1
Bader, G; Han, P; Liu, J; Lu, J; Lv, X; Ma, J; Pan, C; Xing, X; Zheng, S	1
Alexander, CM; Berger, JP; Carr, RD; Katzeff, HL; Thornberry, N; Xu, SS	1
Dotta, F; Fondelli, C; Guarino, E; Nigi, L; Patti, A	1
Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM	1
He, YL; Jusko, WJ; Landersdorfer, CB	2
He, YL; Irie, S; Ito, H; Sekiguchi, K; Shimada, S; Terao, S; Yamaguchi, M	1
Cao, F; Li, W; Liu, B; Shen, M; Sun, D; Wang, S; Zhang, Z	1
Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Maffioli, P; Ragonesi, PD; Romano, D	1
Cheetham, S; Francis, J; Kirby, M; Poucher, SM; Vickers, SP; Zinker, B	1
Sehra, D; Sehra, S	1
Dejager, S; Foley, JE; Schweizer, A	1
Fisman, EZ; Goldenberg, I; Klempfner, R; Leor, J; Tenenbaum, A	1
Barbieri, M; Marfella, R; Paolisso, G; Rizzo, MR	2
Frier, BM; Inkster, B; Zammitt, NN	1
Groop, PH; Kothny, W; Lukashevich, V; Shao, Q	1
Ishikawa, M; Yamada, Y	1
Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D	1
Colette, C; Dejager, S; Guerci, B; Huet, D; Monnier, L; Petit, C; Quéré, S; Raccah, D; Serusclat, P; Valensi, P	1
Chiamvimonvat, N; Cummings, BP; Despa, F; Despa, S; Dong, H; Dutrow, G; Evans, JE; Graham, J; Guglielmino, K; Hammock, BD; Harris, TR; Havel, PJ; Jackson, K; Vu, V	1
Ando, K; Irako, T; Nishimura, R; Sakamoto, M; Tsujino, D; Utsunomiya, K	1
Arnold, ME; Bonacorsi, SJ; Cao, KK; Christopher, LJ; Cojocaru, L; Dueker, SR; Humphreys, WG; Keung, CF; Lohstroh, PN; Shen, JX; Stouffer, B; Xu, XS	1
Nakamura, A; Terauchi, Y	1
Charbonnel, B; Delibasi, T; Farmer, I; Hermans, MP; Jörgens, S; Lohm, L; Maheux, P; Malvolti, E; Piatti, P	1
Abe, Y; Anabuki, J; Fukuda-Tsuru, S; Ishii, S; Yoshida, K	1
Foley, J; Gallwitz, B; Kothny, W; Kozlovski, P; Lukashevich, V; Shao, Q	1
Buikema, H; Deelman, LE; Hammes, HP; Henning, RH; Landheer, S; van Amerongen, A; van Gilst, WH; Wang, Y	1
Higashi, Y; Inoue, G; Nakata, H; Ohtomo, Y; Otsu, S; Sugitani, S; Yamaji, S	1
Ali, S; Fonseca, V	1
Barbieri, M; Campitiello, F; Canonico, R; Canonico, S; Carbonara, O; Della Corte, A; Ferraraccio, F; Gualdiero, P; Marfella, R; Padovano, V; Paolisso, G; Paolisso, P; Petrella, A; Petronella, P; Rizzo, MR; Sasso, FC	1
Matikainen, N; Taskinen, MR	1
Favarato, D; Garzillo, CL; Girardi, P; Hueb, W; Kalil Filho, R; Lima, EG; Rahmi, RM; Ramires, JA; Rezende, PC; Strunz, CM; Takiuti, M; Uchida, AH	1
Devries, JH	1
Bhat, N; Krishnamurthy, AN; Kunjathaya, P; Ramaswami, PK	1
Itoh, H; Saisho, Y	1
Akhtar, M; Imran, M; Khan, S; Najmi, AK; Pillai, KK	1
Barbieri, M; Boccardi, V; Esposito, A; Marfella, R; Pansini, A; Paolisso, G; Rizzo, MR	1
Dickinson, S; Foley, JE; Groop, PH; Kothny, W; Lukashevich, V; Schweizer, A	1
Berndt-Zipfel, C; Dworak, M; Forst, T; Klamp, I; Löffler, A; Mitry, M; Pfützner, A	1
Dhakad, PK; Joshi, M; Joshi, S; Kanawat, DS; Kurmi, MK; Mishra, A; Raikwar, SK; Sharma, AK; Sharma, P; Srinivasan, BP; Srivastava, V	1
Brinkman, JA; Burkey, BF; Dunning, BE; Hughes, TE; Mangold, BL; Naderi, GB; Prasad, K; Russell, ME; Villhauer, EB	1
Ahrén, B; Holmes, D; Jansson, PA; Landin-Olsson, M; Schweizer, A; Svensson, M	1
Barlocco, D	1
Ahrén, B; Gomis, R; Mills, D; Schweizer, A; Standl, E	1
Deacon, CF; Dunning, BE; Foley, JE; He, YL; Holst, JJ; Ligueros-Saylan, M; Mari, A; Sallas, WM; Watson, C	1
Abboa-Offei, B; Augeri, DJ; Betebenner, DA; Biller, SA; Cap, M; Chang, SY; Egan, DM; Hamann, LG; Han, SP; Huang, Q; Khanna, A; Kirby, MS; Magnin, DR; Marcinkeviciene, J; Parker, RA; Robertson, JG; Robl, JA; Simpkins, LM; Tao, L; Taunk, P; Tozzo, E; Wang, A; Welzel, GE; Xin, L	1
Berenbeim, DM; Gilkin, RJ; Gleeson, JM	1
Byiers, S; Foley, J; Holmes, D; Ristic, S	1
Edelman, SV	1
Lebovitz, H	1
Heinzl, S	1
Dunning, BE; Foley, JE; Mänttäri, S; Matikainen, N; Mills, D; Schweizer, A; Taskinen, MR; Ulvestad, A	1
Galbreath, E; Holmes, D; Jauffret-Kamel, S; Pratley, RE	1
Bates, PC; Ristic, S	1
Inoue, T; Kira, K; Nagakura, T; Saeki, T; Shinoda, M; Tanaka, I; Yamazaki, K; Yasuda, N	1
Barnett, A	1
Choukem, SP; Gautier, JF	1
Drucker, DJ; Nauck, MA	1
Henness, S; Keam, SJ	1
Foley, JE; He, YL; Horowitz, A; Ligueros-Saylan, M; Sallas, W; Watson, CE	1
Chang, CN; Chao, YS; Chen, CT; Chen, X; Cheng, JH; Chien, CH; Coumar, MS; Han, CH; Hsieh, HP; Hsu, LJ; Hsu, T; Huang, YW; Jiaang, WT; Tsai, TY; Wu, HY; Wu, SH	1
Dejager, S; Mills, D; Pi-Sunyer, FX; Schweizer, A	1
Baig, MR; Balas, B; Cusi, K; Darland, C; Deacon, CF; DeFronzo, RA; Dunning, BE; Foley, JE; He, YL; Holst, JJ; Ligueros-Saylan, M; Mari, A; Wang, Y; Watson, C	1
Biollaz, J; Buclin, T; Grouzmann, E	1
Baron, MA; Dejager, S; Mills, D; Rosenstock, J; Schweizer, A	1
Bosi, E; Camisasca, RP; Collober, C; Garber, AJ; Rochotte, E	1
Baron, MA; Dejager, S; Garber, AJ; Rochotte, E; Schweizer, A	1
Baron, MA; Camisasca, RP; Couturier, A; Cressier, F; Dejager, S; Kim, SW; Rosenstock, J	1
Dejager, S; Foley, JE; Razac, S; Schweizer, A	1
Winkler, G	1
Albrecht, D; Baron, MA; Chang, I; Dejager, S; Fonseca, V; Schweizer, A	1
Pratley, RE; Salsali, A	1
Bullock, JM; Deacon, CF; Dunning, BE; Foley, JE; He, YL; Holst, JJ; Ligueros-Saylan, M; Wang, Y	1
Helms, K; Kleppinger, EL	1
Couturier, A; Dejager, S; Foley, JE; Schweizer, A	1
Bloomgarden, ZT; Inzucchi, SE	1
Klein, HH; Meier, JJ; Schmidt, WE	1
Marrs, JC; Saseen, JJ	1
Lauster, CD; McKaveney, TP; Muench, SV	1
Del Prato, S	1
Campestrini, J; Deacon, CF; He, YL; Holst, JJ; Ligueros-Saylan, M; Nielsen, JC; Riviere, GJ; Schwartz, S; Serra, D; Wang, Y	1
Amori, RE; Lau, J; Pittas, AG	1
Jennings, HR; Langley, AK; Suffoletta, TJ	1
Panina, G	1
Banerji, MA; Couturier, A; Dejager, S; Pi-Sunyer, FX; Pratley, RE; Rosenstock, J; Schweizer, A	1
Dunning, BE; Foley, JE; Jauffret, S; Lalanne, G; Mari, A; Nilsson, PM; Scherbaum, WA; Schweizer, A	1
Ahrén, B; Foley, JE; Pacini, G; Schweizer, A; Tura, A	1
Bolli, G; Cohen, SE; Dotta, F; Rochotte, E	1
Azuma, K; Cobelli, C; Dalla Man, C; Deacon, CF; Foley, JE; He, Y; Holst, JJ; Kangani, C; Kelley, DE; Ligueros-Saylan, M; Mancino, J; Rádiková, Z; Serra, D; Thomas, E; Toledo, FG	1
Banerji, MA; Dejager, S; Foley, JE; Mills, D; Pi-Sunyer, FX; Pratley, RE; Rosenstock, J; Schweizer, A	1
Garber, AJ; Sharma, MD	1
Cefalu, WT; Urquhart, S	1
Foley, JE; Jauffret, S; Lalanne, G; Mari, A; Nilsson, PM; Scherbaum, WA; Schweizer, A	1
Göke, B	1
Ahrén, B; Foley, JE	1
Fitchet, M; Rosenstock, J	1
Banerji, MA; Baron, MA; Camisasca, RP; Couturier, A; Ebeling, P; Foley, JE; Garber, AJ; Gudbjörnsdottir, S	1
Bock, G; Burton, DB; Camilleri, M; Deacon, CF; Foley, JE; Giesler, PD; Rizza, RA; Saylan, ML; Serra, DB; Vella, A	1
Barona, JP; Foley, JE; Mohideen, P; Niggli, M; Pan, C; Wang, Y; Yang, W	1
List, JF; Rosenstock, J; Sankoh, S	1
Dunning, BE; Foley, JE; Lalanne, G; Mari, A; Nilsson, PM; Scherbaum, WA; Schweizer, A; Wang, Y	1
Baron, M; Dejager, S; Fonseca, V; Shao, Q	1
Bartberger, MD; Castro, VM; Chen, M; Emery, M; Fotsch, C; Gustafsson, S; Hale, C; Hickman, D; Homan, E; Johansson, L; Jordan, SR; Komorowski, R; Li, A; Matsumoto, G; McRae, K; Moniz, G; Orihuela, C; Palm, G; Veniant, M; Wang, M; Williams, M; Zhang, J	1
Burkey, BF; Foley, JE; Hassiepen, U; Hoffmann, PK; Juedes, M; Trappe, J	1
Bandeira-Echtler, E; Bergerhoff, K; Lerch, CL; Richter, B	1
Hammock, BD; Imig, JD; Kim, IH; Luria, A; Mitchell, BC; Newman, JW; Olearczyk, JJ; Quigley, JE; Yamamoto, T	1
Campestrini, J; Flannery, B; He, YL; Jarugula, V; Leon, S; Ligueros-Saylan, M; Zinny, MA	1

Reviews

183 review(s) available for adamantane and Diabetes Mellitus, Adult-Onset

Article	Year
Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials. Diabetes research and clinical practice, 2020, Volume: 159 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Randomized Controlled Trials as Topic; Sitagliptin Phosphate	2020
Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. Acta diabetologica, 2020, Volume: 57, Issue:6 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incidence; Neoplasms; Piperidines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Uracil; Vildagliptin	2020
Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis. Medicine, 2020, Jul-24, Volume: 99, Issue:30 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors	2020
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. The Cochrane database of systematic reviews, 2020, 07-30, Volume: 8 Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Glycated Hemoglobin; Graft Survival; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Kidney Transplantation; Nitriles; Pioglitazone; Postoperative Complications; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Transplant Recipients; Vildagliptin	2020
Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:17 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Hypoglycemia; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2020
An overview of therapeutic potential of N-alkylated 1-deoxynojirimycin congeners. Carbohydrate research, 2021, Volume: 504 Topics: 1-Deoxynojirimycin; Adamantane; Animals; Diabetes Mellitus, Type 2; Female; Swine	2021
Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2021, 09-22, Volume: 31, Issue:10 Topics: Adamantane; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Disease Risk Factors; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Time Factors; Treatment Outcome	2021
SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus. Postgraduate medicine, 2017, Volume: 129, Issue:4 Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Sodium-Glucose Transporter 2 Inhibitors	2017
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:7 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil	2017
Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:5 Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors	2017
Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. Expert review of pharmacoeconomics & outcomes research, 2017, Volume: 17, Issue:2 Topics: Adamantane; Brazil; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Models, Economic; Nitriles; Pyrrolidines; Vildagliptin	2017
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. The Cochrane database of systematic reviews, 2017, 05-10, Volume: 5 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Nitriles; Peptides; Pyrrolidines; Randomized Controlled Trials as Topic; Risk Factors; Venoms; Vildagliptin	2017
A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 92 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Treatment Outcome; Vildagliptin	2017
Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials. Journal of diabetes and its complications, 2017, Volume: 31, Issue:9 Topics: Adamantane; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Tumor Necrosis Factor-alpha; Vildagliptin	2017
Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes. The Annals of pharmacotherapy, 2018, Volume: 52, Issue:1 Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Tablets	2018
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin. Cardiovascular diabetology, 2017, 09-13, Volume: 16, Issue:1 Topics: Adamantane; Animals; Cardiotoxins; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Randomized Controlled Trials as Topic	2017
Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. Expert review of clinical pharmacology, 2017, Volume: 10, Issue:12 Topics: Adamantane; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Tablets	2017
Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. BMC pharmacology & toxicology, 2017, 10-23, Volume: 18, Issue:1 Topics: Adamantane; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nitriles; Pioglitazone; Pyrrolidines; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Vildagliptin	2017
Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis. PloS one, 2018, Volume: 13, Issue:5 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Randomized Controlled Trials as Topic	2018
New Medications for the Treatment of Diabetes. Diabetes technology & therapeutics, 2019, Volume: 21, Issue:S1 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2019
Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin. Vascular health and risk management, 2013, Volume: 9 Topics: Adamantane; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin; Weight Gain	2013
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? Hospital practice (1995), 2013, Volume: 41, Issue:2 Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2013
[Use of vildagliptin from an internal disease specialists point of view]. Vnitrni lekarstvi, 2013, Volume: 59, Issue:4 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin	2013
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgraduate medicine, 2013, Volume: 125, Issue:3 Topics: Adamantane; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular System; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Lipids; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin. International journal of clinical practice, 2013, Volume: 67, Issue:8 Topics: Adamantane; Area Under Curve; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Treatment Outcome	2013
Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes/metabolism research and reviews, 2014, Volume: 30, Issue:7 Topics: Adamantane; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Incretins; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome	2014
Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies. Journal of managed care pharmacy : JMCP, 2014, Volume: 20, Issue:2 Topics: Adamantane; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Treatment Outcome	2014
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovascular diabetology, 2014, Feb-04, Volume: 13 Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Randomized Controlled Trials as Topic	2014
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes. Advances in therapy, 2014, Volume: 31, Issue:3 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss	2014
Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes. Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:4 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin	2014
Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs, 2014, Volume: 74, Issue:5 Topics: Adamantane; Administration, Oral; Aged; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Vildagliptin	2014
Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:10 Topics: Adamantane; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Piperidines; Renal Insufficiency; Risk Factors; Treatment Outcome; Uracil	2014
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:6 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin	2014
Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2014, Volume: 24, Issue:7 Topics: Acute Disease; Adamantane; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Hospitalization; Humans; Incidence; Randomized Controlled Trials as Topic; Risk Factors	2014
Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:9 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Insulin; Metformin; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin	2014
Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:2 Topics: Adamantane; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Glycated Hemoglobin; Humans; Hypoglycemia; Nitriles; Practice Guidelines as Topic; Pyrrolidines; Quality of Life; Vildagliptin	2015
Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes. Vascular health and risk management, 2014, Volume: 10 Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Fasting; Female; Humans; Linear Models; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vildagliptin; Weight Gain; Weight Loss	2014
Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure? Clinical therapeutics, 2014, Dec-01, Volume: 36, Issue:12 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Hospitalization; Humans; Nitriles; Piperidines; Pyrrolidines; Sitagliptin Phosphate; Uracil; Vildagliptin	2014
Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease. Vascular health and risk management, 2015, Volume: 11 Topics: Adamantane; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Risk Assessment; Risk Factors; Treatment Outcome	2015
Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue? International journal of cardiology, 2015, Apr-01, Volume: 184 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incidence; Myocardial Infarction; Patient Outcome Assessment; Patient Selection; Piperidines; Research Design; Time Factors; Uracil	2015
Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:7 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Holidays; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Liraglutide; Nitriles; Observational Studies as Topic; Pioglitazone; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Vildagliptin; Weight Loss	2015
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. Diabetes & vascular disease research, 2015, Volume: 12, Issue:3 Topics: Adamantane; Animals; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incretins; Piperidines; Protective Factors; Risk Assessment; Risk Factors; Treatment Outcome; Uracil	2015
Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2015, Volume: 25, Issue:8 Topics: Adamantane; Administration, Oral; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Sitagliptin Phosphate; Thiazolidinediones	2015
Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:11 Topics: Adamantane; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Retrospective Studies; Vildagliptin	2015
Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective. Current diabetes reports, 2015, Volume: 15, Issue:11 Topics: Adamantane; Cardiovascular System; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Piperidines; Sitagliptin Phosphate; Treatment Outcome; Uracil	2015
Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:15 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Urinary Tract Infections	2015
Saxagliptin: A Review in Type 2 Diabetes. Drugs, 2015, Volume: 75, Issue:15 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Treatment Outcome	2015
Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety. Advances in therapy, 2015, Volume: 32, Issue:11 Topics: Adamantane; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents	2015
[The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?]. Vnitrni lekarstvi, 2015, Volume: 61, Issue:11 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Piperidines; Sitagliptin Phosphate; Uracil	2015
Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine, 2016, Volume: 52, Issue:3 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Nitriles; Pancreatitis; Pyrrolidines; Treatment Outcome; Vildagliptin	2016
Cardiovascular Effects of Incretin-Based Therapies. Annual review of medicine, 2016, Volume: 67 Topics: Adamantane; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Piperidines; Sitagliptin Phosphate; Uracil	2016
Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes. Expert opinion on drug metabolism & toxicology, 2016, Volume: 12, Issue:4 Topics: Adamantane; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Insulin; Meta-Analysis as Topic; Postprandial Period; Randomized Controlled Trials as Topic; Risk Factors; Sulfonylurea Compounds; Treatment Outcome	2016
Saxagliptin for the treatment of diabetes - a focus on safety. Expert opinion on drug safety, 2016, Volume: 15, Issue:5 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Hospitalization; Humans; Hypoglycemia; Hypoglycemic Agents; Randomized Controlled Trials as Topic	2016
[Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials]. Orvosi hetilap, 2016, Apr-17, Volume: 157, Issue:16 Topics: Adamantane; Cardiovascular System; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Peptides; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Uracil	2016
Adamantane - A Lead Structure for Drugs in Clinical Practice. Current medicinal chemistry, 2016, Volume: 23, Issue:29 Topics: Adamantane; Alzheimer Disease; Antiviral Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Influenza, Human	2016
Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor. Clinical pharmacokinetics, 2017, Volume: 56, Issue:1 Topics: Adamantane; Area Under Curve; Cytochrome P-450 CYP3A; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glucagon-Like Peptide 1; Half-Life; Humans; Hypoglycemic Agents; Metabolic Clearance Rate	2017
Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients. Journal of diabetes research, 2016, Volume: 2016 Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide-1 Receptor; Glucosides; Holidays; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Liraglutide; Nitriles; Peptides; Pyrrolidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Venoms; Vildagliptin	2016
Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes. Diabetes care, 2017, Volume: 40, Issue:2 Topics: Acute Disease; Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incidence; Pancreatitis; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil	2017
Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Advances in therapy, 2017, Volume: 34, Issue:1 Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Meta-Analysis as Topic; Peptides; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil	2017
Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China. PloS one, 2016, Volume: 11, Issue:11 Topics: Adamantane; Asian People; Cardiovascular Diseases; China; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Male; Metformin; Models, Economic; Quality of Life	2016
Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. Lipids in health and disease, 2016, Nov-23, Volume: 15, Issue:1 Topics: Adamantane; Adiponectin; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Vildagliptin	2016
Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes. Clinical pharmacokinetics, 2017, Volume: 56, Issue:7 Topics: Adamantane; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Linagliptin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2017
Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus. Drugs, 2017, Volume: 77, Issue:3 Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Glucosides; Humans; Hypoglycemic Agents	2017
Saxagliptin and Heart Failure in the SAVOR-TIMI 53 Trial: Reflections on the Bradford Hill Criteria. Revista espanola de cardiologia (English ed.), 2017, Volume: 70, Issue:12 Topics: Adamantane; Causality; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Hospitalization; Humans; Proportional Hazards Models	2017
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Frontiers in bioscience : a journal and virtual library, 2008, May-01, Volume: 13 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Current opinion in clinical nutrition and metabolic care, 2008, Volume: 11, Issue:4 Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vascular health and risk management, 2008, Volume: 4, Issue:2 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin	2008
From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Current opinion in drug discovery & development, 2008, Volume: 11, Issue:4 Topics: Adamantane; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Nitriles; Protein Conformation; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Structure-Activity Relationship; Treatment Outcome; Triazoles; Vildagliptin	2008
New treatments for type 2 diabetes--the DPP4 inhibitors. Primary care diabetes, 2007, Volume: 1, Issue:4 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin	2007
DPP4 inhibitors: a new approach in diabetes treatment. Advances in therapy, 2008, Volume: 25, Issue:7 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes. Arquivos brasileiros de endocrinologia e metabologia, 2008, Volume: 52, Issue:6 Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Postprandial Period; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vascular health and risk management, 2008, Volume: 4, Issue:3 Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Combinations; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Metformin; Nitriles; Pyrrolidines; Tablets; Treatment Outcome; Vildagliptin	2008
[Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?]. Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:43 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. Cardiology clinics, 2008, Volume: 26, Issue:4 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs, 2008, Volume: 68, Issue:16 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin	2008
Incretin-based therapies in type 2 diabetes: a review of clinical results. Diabetes research and clinical practice, 2008, Dec-15, Volume: 82 Suppl 2 Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. IDrugs : the investigational drugs journal, 2008, Volume: 11, Issue:12 Topics: Adamantane; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Patents as Topic; Structure-Activity Relationship	2008
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vascular health and risk management, 2008, Volume: 4, Issue:4 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin	2008
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV. Current topics in medicinal chemistry, 2008, Volume: 8, Issue:17 Topics: Adamantane; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrrolidines; Uracil; Vildagliptin	2008
Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. Mymensingh medical journal : MMJ, 2009, Volume: 18, Issue:1 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2009
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. Advances in therapy, 2009, Volume: 26, Issue:3 Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Pioglitazone; Piperidines; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Uracil	2009
Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta bio-medica : Atenei Parmensis, 2008, Volume: 79, Issue:3 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
Drug evaluation: vildagliptin-metformin single-tablet combination. Advances in therapy, 2009, Volume: 26, Issue:2 Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Lipids; Metformin; Nitriles; Practice Guidelines as Topic; Pyrrolidines; Safety; Treatment Outcome; Vildagliptin	2009
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Advances in therapy, 2009, Volume: 26, Issue:3 Topics: Adamantane; Age Factors; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Randomized Controlled Trials as Topic; Sex Factors; Time Factors	2009
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. Vascular health and risk management, 2008, Volume: 4, Issue:6 Topics: Adamantane; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Vildagliptin	2008
Vildagliptin: a new oral treatment for type 2 diabetes mellitus. Vascular health and risk management, 2008, Volume: 4, Issue:6 Topics: Adamantane; Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Nitriles; Pyrrolidines; Severity of Illness Index; Time Factors; Treatment Outcome; Vildagliptin	2008
The scientific evidence: vildagliptin and the benefits of islet enhancement. Diabetes, obesity & metabolism, 2009, Volume: 11 Suppl 2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Evidence-Based Medicine; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Islets of Langerhans; Metformin; Nitriles; Pyrrolidines; Vildagliptin	2009
Translating science into clinical practice: focus on vildagliptin in combination with metformin. Diabetes, obesity & metabolism, 2009, Volume: 11 Suppl 2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Thiazolidinediones; Vildagliptin	2009
[The value of incretin based therapies]. Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:20 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2009
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Advances in therapy, 2009, Volume: 26, Issue:5 Topics: Adamantane; Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Safety; Treatment Outcome	2009
[Pharmacological sheet. Vildagliptin, oral administration (GALVUS)]. Journal de pharmacie de Belgique, 2009, Issue:2 Topics: Adamantane; Contraindications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin	2009
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events. Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:4 Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Metformin; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sensitivity and Specificity; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin	2009
Defining the importance of daily glycemic control and implications for type 2 diabetes management. Postgraduate medicine, 2009, Volume: 121, Issue:5 Topics: Adamantane; Blood Glucose Self-Monitoring; Circadian Rhythm; Cost of Illness; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic Index; Humans; Incretins; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Triazoles	2009
Vildagliptin in clinical practice: a review of literature. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:16 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Islets of Langerhans; Nitriles; Pyrrolidines; Vildagliptin	2009
Exploration of the DPP-4 inhibitors with a focus on saxagliptin. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:17 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans	2009
DPP-4 inhibitors in clinical practice. Postgraduate medicine, 2009, Volume: 121, Issue:6 Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2009
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleveland Clinic journal of medicine, 2009, Volume: 76 Suppl 5 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glutaminase; Homeostasis; Humans; Hypoglycemic Agents; Incretins; Intracellular Signaling Peptides and Proteins; Peptides; Pyrazines; Signal Transduction; Sitagliptin Phosphate; Triazoles; Venoms	2009
Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs. Postgraduate medicine, 2010, Volume: 122, Issue:1 Topics: Adamantane; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Sulfonylurea Compounds	2010
[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia]. Pharmazie in unserer Zeit, 2010, Volume: 39, Issue:2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2010
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature]. Nederlands tijdschrift voor geneeskunde, 2010, Volume: 154 Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin	2010
The physiologic role of incretin hormones: clinical applications. The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:3 Suppl 2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil	2010
Saxagliptin: a new drug for the treatment of type 2 diabetes. Mini reviews in medicinal chemistry, 2010, Volume: 10, Issue:8 Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Humans; Hypoglycemic Agents; Incretins; Protease Inhibitors	2010
Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. Current medical research and opinion, 2010, Volume: 26, Issue:7 Topics: Adamantane; Administration, Oral; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin	2010
Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes. The Annals of pharmacotherapy, 2010, Volume: 44, Issue:6 Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Headache; Humans; Respiratory Tract Infections	2010
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:6 Topics: Adamantane; Cerebrovascular Disorders; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Vildagliptin	2010
Managing type 2 diabetes in the primary care setting: beyond glucocentricity. The American journal of the medical sciences, 2010, Volume: 340, Issue:2 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin	2010
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:8 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Half-Life; Humans; Hypoglycemic Agents; Male; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin	2010
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology, 2010, Volume: 86, Issue:1 Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Weight Loss	2010
Incretin physiology and its role in type 2 diabetes mellitus. The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:7 Suppl 7 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms	2010
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health technology assessment (Winchester, England), 2010, Volume: 14, Issue:36 Topics: Adamantane; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Nitriles; Peptides; Pyrazines; Pyrrolidines; Quality of Life; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; State Medicine; Thiazolidinediones; Triazoles; United Kingdom; Venoms; Vildagliptin	2010
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clinical pharmacokinetics, 2010, Volume: 49, Issue:9 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2010
DPP-4 inhibitors: what may be the clinical differentiators? Diabetes research and clinical practice, 2010, Volume: 90, Issue:2 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2010
Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vascular health and risk management, 2010, Aug-09, Volume: 6 Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Nitriles; Pyrrolidines; Vildagliptin; Weight Gain	2010
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. The American journal of managed care, 2010, Volume: 16, Issue:7 Suppl Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Liraglutide; Managed Care Programs; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2010
Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2010, Sep-15, Volume: 67, Issue:18 Topics: Adamantane; Adult; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins	2010
Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs, 2010, Nov-12, Volume: 70, Issue:16 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin	2010
Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:3 Topics: Adamantane; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin	2011
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. Postgraduate medicine, 2011, Volume: 123, Issue:1 Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2011
Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Current medical research and opinion, 2011, Volume: 27, Issue:4 Topics: Adamantane; Adolescent; Adult; Age Factors; Aged; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Multicenter Studies as Topic; Placebos; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Young Adult	2011
The many faces of the adamantyl group in drug design. European journal of medicinal chemistry, 2011, Volume: 46, Issue:6 Topics: Adamantane; Animals; Antimalarials; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Iron Chelating Agents; Iron Overload; Malaria; Solubility	2011
Saxagliptin/metformin (kombiglyze XR) for type 2 diabetes. The Medical letter on drugs and therapeutics, 2011, Mar-21, Volume: 53, Issue:1360 Topics: Adamantane; Animals; Clinical Trials as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations; Humans; Hypoglycemic Agents; Metformin	2011
Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vascular health and risk management, 2011, Volume: 7 Topics: Adamantane; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Consumer Product Safety; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Nitriles; Odds Ratio; Pyrrolidines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vildagliptin	2011
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hospital practice (1995), 2011, Volume: 39, Issue:1 Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin	2011
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:9 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Nitriles; Pyrrolidines; Vildagliptin	2011
[Vildagliptin]. Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69, Issue:5 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin	2011
Vildagliptin in the treatment of type 2 diabetes mellitus. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:12 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Nitriles; Pyrrolidines; Vildagliptin	2011
Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes. The Journal of the Association of Physicians of India, 2011, Volume: 59 Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Nitriles; Pyrrolidines; Vildagliptin	2011
Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: predictive factors of the treatment response in type 2 diabetes. Annales d'endocrinologie, 2011, Volume: 72, Issue:4 Topics: Adamantane; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fasting; Food; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic	2011
Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. Clinical therapeutics, 2011, Volume: 33, Issue:8 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents	2011
Place in therapy for liraglutide and saxagliptin for type 2 diabetes. Southern medical journal, 2011, Volume: 104, Issue:6 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Incretins; Liraglutide	2011
Recent diabetes issues affecting the primary care clinician. Southern medical journal, 2011, Volume: 104, Issue:6 Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Primary Health Care; Rosiglitazone; Thiazolidinediones; Vitamin B 12 Deficiency	2011
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs]. Orvosi hetilap, 2011, Sep-11, Volume: 152, Issue:37 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin	2011
Glycosphingolipids and insulin resistance. Advances in experimental medicine and biology, 2011, Volume: 721 Topics: 1-Deoxynojirimycin; Adamantane; Animals; Cardiovascular Diseases; Ceramides; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Fatty Acids; Fatty Liver; Gaucher Disease; Glucosyltransferases; Glycosphingolipids; Humans; Insulin Resistance; Metabolic Syndrome; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Pyrrolidines; Receptor, Insulin; Signal Transduction	2011
[Incretin-based therapy for treating patients with type 2 diabetes]. Orvosi hetilap, 2011, Nov-27, Volume: 152, Issue:48 Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin	2011
Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:6 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies. Annals of medicine, 2012, Volume: 44, Issue:2 Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Risk	2012
Metformin + saxagliptin for type 2 diabetes. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:1 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin	2012
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. Journal of clinical pharmacology, 2012, Volume: 52, Issue:10 Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2012
The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Journal of clinical pharmacy and therapeutics, 2012, Volume: 37, Issue:4 Topics: Adamantane; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Vildagliptin	2012
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes & metabolism, 2012, Volume: 38, Issue:2 Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain	2012
Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. Drugs, 2012, Jan-22, Volume: 72, Issue:2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; European Union; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic	2012
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovascular diabetology, 2012, Jan-16, Volume: 11 Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Patient Safety; Proportional Hazards Models; Risk Assessment; Risk Factors; Treatment Outcome	2012
Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:3 Topics: Adamantane; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Kidney; Metformin; Patient Selection; Risk Assessment; Risk Factors; Treatment Outcome	2012
Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes technology & therapeutics, 2012, Volume: 14, Issue:4 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Purines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Vildagliptin	2012
Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clinical pharmacokinetics, 2012, Mar-01, Volume: 51, Issue:3 Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Nitriles; Patient Selection; Pyrrolidines; Risk Assessment; Risk Factors; Treatment Outcome; Vildagliptin	2012
Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:9 Topics: Adamantane; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Metformin; Nitriles; Pyrrolidines; Tablets; Treatment Outcome; Vildagliptin	2012
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors. Current diabetes reviews, 2012, Volume: 8, Issue:3 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2012
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. Vascular health and risk management, 2012, Volume: 8 Topics: Adamantane; Age Factors; Aged; Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Glycated Hemoglobin; Humans; Middle Aged; Nitriles; Patient Selection; Prediabetic State; Pyrrolidines; Risk Assessment; Severity of Illness Index; Treatment Outcome; Vildagliptin	2012
Drug-induced hypoglycaemia in type 2 diabetes. Expert opinion on drug safety, 2012, Volume: 11, Issue:4 Topics: Adamantane; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Peptides; Pharmacogenetics; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms	2012
Saxagliptin overview: special focus on safety and adverse effects. Expert opinion on drug safety, 2013, Volume: 12, Issue:1 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Dosage Calculations; Drug Interactions; Humans; Kidney Diseases; Liver Diseases; Patient Selection; Risk Assessment; Risk Factors; Treatment Outcome	2013
Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus--targeting thrombogenesis. Expert opinion on therapeutic targets, 2013, Volume: 17, Issue:6 Topics: Adamantane; Animals; Anti-Inflammatory Agents; Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Fibrinolytic Agents; Humans; Hypoglycemic Agents; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Thrombosis; Vildagliptin	2013
LAF-237 (Novartis). Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:10 Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Humans; Protease Inhibitors; Pyrrolidines; Structure-Activity Relationship; Treatment Outcome	2004
Incretin mimetics: promising new therapeutic options in the treatment of type 2 diabetes. Journal of managed care pharmacy : JMCP, 2005, Volume: 11, Issue:7 Suppl Topics: Adamantane; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Peptides; Pyrrolidines; Venoms	2005
Incretins: what does the future hold? Diabetes technology & therapeutics, 2005, Volume: 7, Issue:5 Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Exenatide; Glucagon-Like Peptide 1; Humans; Liraglutide; Nitriles; Peptides; Protease Inhibitors; Pyrrolidines; Venoms; Vildagliptin	2005
Diabetes: assessing the pipeline. Atherosclerosis. Supplements, 2006, Volume: 7, Issue:1 Topics: Adamantane; Alkanesulfonates; Amyloid; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exenatide; Glycine; Humans; Hypoglycemic Agents; Indoles; Islet Amyloid Polypeptide; Maleimides; Nitriles; Oxazoles; Peptides; Phenylpropionates; Piperidines; PPAR alpha; PPAR gamma; Protein Kinase C; Pyrazoles; Pyrrolidines; Receptor, Cannabinoid, CB1; Receptors, Glucagon; Rimonabant; Venoms; Vildagliptin	2006
Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:4 Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Isoenzymes; Nitriles; Pyrrolidines; Vildagliptin	2006
[Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists]. Medizinische Monatsschrift fur Pharmazeuten, 2006, Volume: 29, Issue:3 Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glycine; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Oxazoles; Peroxisome Proliferator-Activated Receptors; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes. Drugs of today (Barcelona, Spain : 1998), 2006, Volume: 42, Issue:8 Topics: Adamantane; Animals; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Humans; Hypoglycemic Agents; Islets of Langerhans; Nitriles; Protease Inhibitors; Pyrrolidines; Stimulation, Chemical; Vildagliptin	2006
DPP-4 inhibitors and their potential role in the management of type 2 diabetes. International journal of clinical practice, 2006, Volume: 60, Issue:11 Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Models, Animal; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
How do different GLP-1 mimetics differ in their actions? Current diabetes reports, 2006, Volume: 6, Issue:5 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrrolidines; Venoms; Vildagliptin	2006
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (London, England), 2006, Nov-11, Volume: 368, Issue:9548 Topics: Adamantane; Adenosine Deaminase Inhibitors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2006
Vildagliptin. Drugs, 2006, Volume: 66, Issue:15 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin	2006
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. Diabetes & vascular disease research, 2006, Volume: 3, Issue:3 Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Isoenzymes; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
Exenatide: a novel approach for treatment of type 2 diabetes. Southern medical journal, 2006, Volume: 99, Issue:11 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Exenatide; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Humans; Hypoglycemic Agents; Insulin; Nitriles; Peptides; Pyrrolidines; Treatment Outcome; Venoms; Vildagliptin	2006
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes care, 2007, Volume: 30, Issue:6 Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2007
[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application]. Orvosi hetilap, 2007, Apr-01, Volume: 148, Issue:13 Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Insulin Resistance; Intestinal Mucosa; Nitriles; Peptide Hormones; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Current medical research and opinion, 2007, Volume: 23, Issue:4 Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose; Glycoproteins; Homeostasis; Humans; Hypoglycemic Agents; Islets of Langerhans; Models, Biological; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2007
The role of vildagliptin in the management of type 2 diabetes mellitus. The Annals of pharmacotherapy, 2007, Volume: 41, Issue:5 Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin	2007
[New concepts in the treatment of type 2 diabetes]. Der Internist, 2007, Volume: 48, Issue:7 Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Nitriles; Peptides; Piperidines; Pyrazines; Pyrazoles; Pyrrolidines; Rimonabant; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Vildagliptin: a novel oral therapy for type 2 diabetes mellitus. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Volume: 64, Issue:12 Topics: Adamantane; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Humans; Nitriles; Pyrrolidines; Vildagliptin	2007
Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes. International journal of clinical practice. Supplement, 2007, Issue:154 Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrrolidines; Vildagliptin	2007
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA, 2007, Jul-11, Volume: 298, Issue:2 Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy, 2007, Volume: 27, Issue:8 Topics: Adamantane; Adenosine Deaminase Inhibitors; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Delivery Systems; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2007
The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond. Diabetes, obesity & metabolism, 2007, Volume: 9 Suppl 1 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Risk Factors; Vildagliptin	2007
DPP-4 inhibitors. Best practice & research. Clinical endocrinology & metabolism, 2007, Volume: 21, Issue:4 Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin	2007
Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:10 Topics: Adamantane; Aged; Biomarkers; Blood Glucose; C-Peptide; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Multicenter Studies as Topic; Nitriles; Pyrrolidines; Vildagliptin	2008
Update: vildagliptin for the treatment of Type 2 diabetes. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:1 Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin	2008
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. Current diabetes reports, 2007, Volume: 7, Issue:5 Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Hypoglycemic Agents; Incretins; Islets of Langerhans; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Clinical management strategies for type 2 diabetes. JAAPA : official journal of the American Academy of Physician Assistants, 2007, Volume: Suppl Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin-Secreting Cells; Metformin; Nitriles; Pyrrolidines; Vildagliptin	2007
The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. International journal of clinical practice. Supplement, 2008, Issue:159 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gastric Emptying; Glucagon-Like Peptide 1; Glucose; Humans; Insulin Resistance; Islets of Langerhans; Lipid Metabolism; Liver; Nitriles; Pyrrolidines; Vildagliptin	2008
Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes. International journal of clinical practice. Supplement, 2008, Issue:159 Topics: Adamantane; Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin	2008
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. The Cochrane database of systematic reviews, 2008, Apr-16, Issue:2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:6 Topics: Adamantane; Body Weight; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nausea; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Vomiting	2008

Trials

233 trial(s) available for adamantane and Diabetes Mellitus, Adult-Onset

Article	Year
Comparison of the Efficacy, Tolerability and Side Effect Profile of Vildagliptin-Metformin with Metformin-GlibenclamideMamong Nigerian. West African journal of medicine, 2021, 08-30, Volume: 38, Issue:8 Topics: Adamantane; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Metformin; Nigeria; Nitriles; Prospective Studies; Pyrrolidines; Vildagliptin	2021
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy. Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:1 Topics: Adamantane; Adipose Tissue; Adolescent; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Magnetic Resonance Imaging; Metformin; Sulfonylurea Compounds; Treatment Outcome	2022
Role of endogenous glucagon-like peptide-1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes. Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:3 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Energy Metabolism; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Insulin; Nitriles; Pyrrolidines; Vildagliptin	2020
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial. Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:6 Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Treatment Outcome	2020
Impact of baseline characteristics on glycemic effects of add-on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus. Journal of diabetes investigation, 2020, Volume: 11, Issue:4 Topics: Acarbose; Adamantane; Aged; Blood Glucose; China; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Postprandial Period; Treatment Outcome	2020
Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: The VILDDIAL study, a randomized, multicentre, prospective study. Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:6 Topics: Adamantane; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Renal Dialysis; Vildagliptin	2020
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial. Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:7 Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome	2020
Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:7 Topics: Adamantane; Adipose Tissue; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Humans; Liver; Metformin	2020
The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor. Annales d'endocrinologie, 2020, Volume: 81, Issue:5 Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Female; Glucosides; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Natriuretic Peptide, Brain; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult	2020
The effects of saxagliptin on cardiac structure and function using cardiac MRI (SCARF). Acta diabetologica, 2021, Volume: 58, Issue:5 Topics: Adamantane; Aged; Biomarkers; C-Reactive Protein; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptides; Female; Follow-Up Studies; Heart; Heart Ventricles; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Stroke Volume; Ventricular Function, Left	2021
Acute and long-term effects of saxagliptin on post-prandial glycemic response in obese patients with impaired glucose tolerance. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2021, 04-09, Volume: 31, Issue:4 Topics: Adamantane; Adult; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; France; Glucose Intolerance; Humans; Male; Middle Aged; Obesity; Pilot Projects; Postprandial Period; Time Factors; Treatment Outcome	2021
Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2017, Volume: 125, Issue:6 Topics: Adamantane; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptides; Endothelial Progenitor Cells; Endothelium, Vascular; Female; Humans; Male; Metformin; Middle Aged	2017
The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study. Cardiovascular diabetology, 2017, 05-22, Volume: 16, Issue:1 Topics: Adamantane; Aged; Biomarkers; C-Reactive Protein; Cardiac Rehabilitation; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation Mediators; Interleukin-1beta; Israel; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Time Factors; Treatment Outcome; Up-Regulation; Vildagliptin	2017
Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes. Diabetes research and clinical practice, 2017, Volume: 130 Topics: Adamantane; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucose Intolerance; Homeostasis; Humans; Insulin Resistance; Life Style; Male; Metformin; Middle Aged; Obesity; Postprandial Period; Prediabetic State; Treatment Outcome	2017
A Double-Blinded Randomized Study Investigating a Possible Anti-Inflammatory Effect of Saxagliptin versus Placebo as Add-On Therapy in Patients with Both Type 2 Diabetes And Stable Coronary Artery Disease. Mediators of inflammation, 2017, Volume: 2017 Topics: Adamantane; Aged; Anti-Inflammatory Agents; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Interleukin-10; Leukocytes, Mononuclear; Lipopolysaccharides; Male; Metformin; Middle Aged	2017
The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus. Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:12 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dinoprost; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin	2017
Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension. Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:18 Topics: Adamantane; Aged; Blood Glucose; C-Peptide; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Placebo Effect; Treatment Outcome	2017
Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:3 Topics: Adamantane; Analysis of Variance; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome	2018
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). Cardiovascular diabetology, 2017, 10-10, Volume: 16, Issue:1 Topics: Adamantane; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin	2017
Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin. Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:18 Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin	2017
Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:4 Topics: Adamantane; Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Insulin; Male; Metformin; Middle Aged; Placebos	2018
Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. Diabetes care, 2018, Volume: 41, Issue:3 Topics: Adamantane; Aged; Body Mass Index; Calibration; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diet; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Endpoint Determination; Female; Humans; Life Style; Male; Middle Aged; Myocardial Infarction; Registries; Risk Assessment; Risk Factors; Secondary Prevention; Stroke	2018
Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial. JAMA cardiology, 2018, 02-01, Volume: 3, Issue:2 Topics: Adamantane; Albuminuria; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Incretins; Male; Renal Insufficiency, Chronic	2018
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:6 Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2018
Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment. BMC endocrine disorders, 2018, Feb-27, Volume: 18, Issue:1 Topics: Adamantane; Adult; Age of Onset; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Glycemic Index; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; Polycystic Ovary Syndrome; Prognosis; Prospective Studies	2018
A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 Diabetes research and clinical practice, 2018, Volume: 139 Topics: Adamantane; Adult; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Brazil; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin	2018
The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial. Cardiovascular diabetology, 2018, 05-03, Volume: 17, Issue:1 Topics: Adamantane; Adult; Aged; Antigens, CD34; Arterial Pressure; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; District of Columbia; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Endothelial Progenitor Cells; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Time Factors; Treatment Outcome; Vascular Stiffness	2018
Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2018, Volume: 50, Issue:5 Topics: Adamantane; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Female; Glucosides; Humans; Insulin-Secreting Cells; Male; Middle Aged	2018
Saxagliptin Upregulates Nesfatin-1 Secretion and Ameliorates Insulin Resistance and Metabolic Profiles in Type 2 Diabetes Mellitus. Metabolic syndrome and related disorders, 2018, Volume: 16, Issue:7 Topics: Acarbose; Adamantane; Aged; Blood Glucose; Calcium-Binding Proteins; Diabetes Mellitus, Type 2; Dipeptides; DNA-Binding Proteins; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Male; Metabolome; Metformin; Middle Aged; Nerve Tissue Proteins; Nucleobindins; Up-Regulation	2018
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:11 Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome; Urinary Tract Infections	2018
Impact of treatment with glibenclamide or vildagliptin on glucose variability after aerobic exercise in type 2 diabetes: A randomized controlled trial. Diabetes research and clinical practice, 2018, Volume: 143 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exercise; Female; Glucose; Glyburide; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin	2018
Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes. The Journal of clinical endocrinology and metabolism, 2019, 01-01, Volume: 104, Issue:1 Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult	2019
Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial. BMJ open, 2018, 09-24, Volume: 8, Issue:9 Topics: Adamantane; Adult; Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Drug Monitoring; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Treatment Outcome	2018
Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. Archives of endocrinology and metabolism, 2018, Volume: 62, Issue:4 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reproductive Tract Infections; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2018
Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). The American journal of cardiology, 2019, 01-01, Volume: 123, Issue:1 Topics: Adamantane; Aged; Cerebrovascular Disorders; Coronary Disease; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Peripheral Vascular Diseases; Prevalence; Risk Factors; Treatment Outcome	2019
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4 Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome	2019
Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4 Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Sulfonylurea Compounds; Weight Gain	2019
Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes. Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:9 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections	2019
Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients. The Journal of the Association of Physicians of India, 2018, Volume: 66, Issue:8 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nitriles; Prospective Studies; Pyrrolidines; Quality of Life; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin	2018
Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes. Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:11 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors	2019
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes/metabolism research and reviews, 2013, Volume: 29, Issue:5 Topics: Adamantane; Aged; Biomarkers; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Overweight; Prevalence; Risk Factors; Severity of Illness Index	2013
Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study. Cardiovascular diabetology, 2013, Apr-08, Volume: 12 Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Erythrocyte Deformability; Female; Germany; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Laser-Doppler Flowmetry; Male; Metformin; Microcirculation; Middle Aged; Nitriles; Pyrrolidines; Regional Blood Flow; Retinal Vessels; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Vildagliptin	2013
Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels. Diabetes technology & therapeutics, 2013, Volume: 15, Issue:7 Topics: Adamantane; Adult; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Kinetics; Male; Middle Aged; Nitriles; Obesity; Overweight; Pyrrolidines; Vildagliptin	2013
RETRACTED: Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients. Pharmacological research, 2013, Volume: 73 Topics: Adamantane; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; GPI-Linked Proteins; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Lectins; Male; Metformin; Middle Aged; Nicotinamide Phosphoribosyltransferase; Nitriles; Pyrrolidines; Serpins; Vildagliptin	2013
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus. Clinical interventions in aging, 2013, Volume: 8 Topics: Adamantane; Aged; Aged, 80 and over; Analysis of Variance; Area Under Curve; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Thiazolidinediones; Treatment Outcome	2013
Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. International journal of clinical practice, 2013, Volume: 67, Issue:4 Topics: Adamantane; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome	2013
Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet (London, England), 2013, Aug-03, Volume: 382, Issue:9890 Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Feasibility Studies; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Nitriles; Precision Medicine; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin	2013
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials. Postgraduate medicine, 2013, Volume: 125, Issue:3 Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Thiazolidinediones	2013
Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:12 Topics: Adamantane; Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; Young Adult	2013
Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes. International journal of clinical pharmacology and therapeutics, 2013, Volume: 51, Issue:8 Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin	2013
Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2013, Volume: 30, Issue:12 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prospective Studies; Time Factors; Treatment Outcome	2013
Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Clinical drug investigation, 2013, Volume: 33, Issue:10 Topics: Adamantane; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Headache; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Time Factors; Treatment Outcome; Urinary Tract Infections; Young Adult	2013
Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study. Cardiovascular diabetology, 2013, Aug-19, Volume: 12 Topics: Adamantane; Age Factors; Asian People; Biomarkers; Body Mass Index; China; Clinical Protocols; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Research Design; Time Factors; Treatment Outcome; Vildagliptin	2013
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14 Topics: Adamantane; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Hypoglycemia; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatitis	2013
Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes. International urology and nephrology, 2014, Volume: 46, Issue:2 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Inositol; Kidney Failure, Chronic; Male; Middle Aged; Nitriles; Prospective Studies; Pyrazoles; Pyrrolidines; Renal Dialysis; Serum Albumin; Thiazolidines; Vildagliptin	2014
[A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition]. Terapevticheskii arkhiv, 2013, Volume: 85, Issue:8 Topics: Absorptiometry, Photon; Adamantane; Blood Glucose; Body Composition; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; Waist Circumference	2013
Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5 Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin	2014
A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5 Topics: Adamantane; Adult; Australia; Blood Glucose; Body Mass Index; Body Weight; Canada; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; India; Korea; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thailand; Treatment Outcome; United Kingdom	2014
[SAVOR TIMI 53 - Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus]. Vnitrni lekarstvi, 2013, Volume: 59, Issue:11 Topics: Adamantane; Aged; Cross-Sectional Studies; Czech Republic; Diabetes Mellitus, Type 2; Dipeptides; Female; Heart Diseases; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Survival Analysis	2013
Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2014, Volume: 14, Issue:1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Kidney Transplantation; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin	2014
[Efficacy and safety of vildagliptin as a second-line therapy vs other oral antidiabetic agents in patients with type 2 diabetes: Czech results within the worldwide prospective cohort EDGE study]. Vnitrni lekarstvi, 2013, Volume: 59, Issue:12 Topics: Adamantane; Adult; Aged; Cohort Studies; Czech Republic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Vildagliptin; Weight Gain	2013
Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia. Current medical research and opinion, 2014, Volume: 30, Issue:5 Topics: Adamantane; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glipizide; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged	2014
Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovascular diabetology, 2014, Jan-14, Volume: 13 Topics: Adamantane; Aged; Blood Flow Velocity; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Male; Microvessels; Middle Aged; Retinal Vessels; Treatment Outcome; Vasodilation	2014
The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus. Diabetes research and clinical practice, 2014, Volume: 103, Issue:3 Topics: Acarbose; Adamantane; Adult; Aged; Cells, Cultured; Cross-Over Studies; Cytokines; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hypoglycemic Agents; Leukocytes, Mononuclear; Lymphocytes; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin	2014
Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:9 Topics: Adamantane; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Meals; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Treatment Outcome; Vildagliptin	2014
Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients. Drug design, development and therapy, 2014, Volume: 8 Topics: Adamantane; Adult; Aged; Arginine; C-Reactive Protein; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Female; Fibrinogen; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitric Oxide; Nitriles; Pyrrolidines; Vildagliptin	2014
Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus. Journal of diabetes, 2015, Volume: 7, Issue:2 Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Case-Control Studies; China; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Glycated Hemoglobin; Glycemic Index; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Prognosis; Pyrrolidines; Risk Factors; Sulfonylurea Compounds; Vildagliptin; Weight Gain; Young Adult	2015
Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2014, Volume: 31, Issue:12 Topics: Adamantane; Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dietary Fats; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Male; Metformin; Middle Aged; Nitriles; Proinsulin; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha; Vildagliptin	2014
Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2014, Volume: 122, Issue:8 Topics: Adamantane; Adult; Asian People; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin	2014
Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial. Diabetic medicine : a journal of the British Diabetic Association, 2014, Volume: 31, Issue:10 Topics: Adamantane; Adolescent; Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Intention to Treat Analysis; Metformin; Middle Aged; Nitriles; Obesity; Overweight; Pyrrolidines; Research Design; Vildagliptin; Young Adult	2014
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. Metabolism: clinical and experimental, 2014, Volume: 63, Issue:7 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Intention to Treat Analysis; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin; Weight Gain; Weight Loss	2014
Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin. Diabetes care, 2014, Volume: 37, Issue:9 Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Humans; Incidence; International Agencies; Male; Middle Aged; Pancreatic Neoplasms; Pancreatitis; Prognosis; Risk Factors	2014
A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vascular health and risk management, 2014, Volume: 10 Topics: Adamantane; Asia; Biomarkers; Blood Glucose; Body Weight; Counseling; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Europe; Fasting; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Medication Adherence; Middle Aged; Middle East; Nitriles; Office Visits; Pyrrolidines; Religion and Medicine; Telephone; Time Factors; Treatment Outcome; Vildagliptin	2014
Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes. Diabetes research and clinical practice, 2014, Volume: 105, Issue:2 Topics: Adamantane; Asian People; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period	2014
Improved Insulin Secretion by Autologous Islet Transplantation, Compared to Oral Antidiabetic Agents, After Distal Pancreatectomy. Cell transplantation, 2015, Volume: 24, Issue:8 Topics: Adamantane; Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; HMGB1 Protein; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans Transplantation; Male; Metformin; Middle Aged; Nitriles; Pancreatectomy; Pancreatic Neoplasms; Pyrrolidines; Transplantation, Autologous; Vascular Endothelial Growth Factor A; Vildagliptin	2015
[The SAVOR-TIMI 53 study]. Giornale italiano di cardiologia (2006), 2014, Volume: 15, Issue:6 Topics: Adamantane; Brain Ischemia; Diabetes Mellitus, Type 2; Dipeptides; Humans; Hypoglycemic Agents; Myocardial Infarction; Research Design	2014
Patients with type 2 diabetes mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin. BMC research notes, 2014, Aug-29, Volume: 7 Topics: Adamantane; Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Insulin; Male; Middle Aged; Nitriles; Placebos; Pyrrolidines; Vildagliptin	2014
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation, 2014, Oct-28, Volume: 130, Issue:18 Topics: Adamantane; Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain; Peptide Fragments; Risk Assessment; Troponin T	2014
Dipeptidyl peptidase-4 inhibitor (vildagliptin) improves glycemic control after meal tolerance test by suppressing glucagon release. Drugs in R&D, 2014, Volume: 14, Issue:4 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Food; Glucagon; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin	2014
Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥ 65 years) with type 2 diabetes. Clinical interventions in aging, 2014, Volume: 9 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Female; Humans; Incretins; Male; Middle Aged; Placebos; Risk Factors; Treatment Outcome	2014
[Therapeutic effect of vildagliptin and insulin aspart injection in elderly patients with type 2 diabetes]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2014, Volume: 34, Issue:10 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections; Insulin Aspart; Nitriles; Pyrrolidines; Vildagliptin	2014
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes care, 2015, Volume: 38, Issue:3 Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections	2015
Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA. Trials, 2014, Nov-04, Volume: 15 Topics: Adamantane; Biomarkers; Blood Glucose; Brazil; Clinical Protocols; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Exercise Test; Glyburide; Glycated Hemoglobin; Hemodynamics; Humans; Hypoglycemic Agents; Nitriles; Oxidative Stress; Predictive Value of Tests; Prospective Studies; Pyrrolidines; Research Design; Time Factors; Treatment Outcome; Vildagliptin	2014
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgraduate medicine, 2014, Volume: 126, Issue:6 Topics: Adamantane; Adult; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fasting; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Metformin; Risk Factors	2014
Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial. Diabetes & metabolism, 2015, Volume: 41, Issue:3 Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Vildagliptin; Young Adult	2015
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes care, 2015, Volume: 38, Issue:4 Topics: Adamantane; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Female; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Renal Insufficiency; Severity of Illness Index; Stroke; Treatment Outcome	2015
Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus. Pharmacological reports : PR, 2015, Volume: 67, Issue:1 Topics: Adamantane; Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, LDL; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin	2015
Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes : Results of the Austrian subpopulation of the EDGE study. Wiener klinische Wochenschrift, 2015, Volume: 127, Issue:7-8 Topics: Adamantane; Administration, Oral; Austria; Biomarkers; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Prevalence; Pyrrolidines; Treatment Outcome; Vildagliptin	2015
Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus. The American journal of cardiology, 2015, Feb-15, Volume: 115, Issue:4 Topics: Adamantane; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Male; Middle Aged; Nitriles; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrrolidines; Time Factors; Treatment Outcome; Vildagliptin	2015
Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:5 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Prospective Studies	2015
Effect of vildagliptin on hepatic steatosis. The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:4 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Fatty Liver; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Triglycerides; Vildagliptin	2015
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes care, 2015, Volume: 38, Issue:6 Topics: Adamantane; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Stroke; Treatment Outcome	2015
Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:7 Topics: Adamantane; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Metformin; Sulfonylurea Compounds; Treatment Outcome	2015
Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin. Diabetes research and clinical practice, 2015, Volume: 108, Issue:3 Topics: Acarbose; Adamantane; Aged; Aged, 80 and over; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome	2015
Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study. Current medical research and opinion, 2015, Volume: 31, Issue:6 Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin, Isophane; Male; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin; Weight Gain	2015
The effects and safety of vildagliptin on cardiac function after acute myocardial infarction. International journal of cardiology, 2015, Jun-01, Volume: 188 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Echocardiography, Doppler; Electrocardiography; Female; Follow-Up Studies; Glomerular Filtration Rate; Glycated Hemoglobin; Heart Function Tests; Humans; Incretins; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Nitriles; Pyrrolidines; Reference Values; Risk Assessment; Stroke Volume; Treatment Outcome; Vildagliptin	2015
Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial. Diabetes research and clinical practice, 2015, Volume: 109, Issue:1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin	2015
Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial. Diabetologia, 2015, Volume: 58, Issue:9 Topics: Adamantane; Aged; Blood Glucose; Brazil; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; United States; Vildagliptin	2015
Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes. Diabetes care, 2015, Volume: 38, Issue:11 Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections	2015
Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes. Diabetes care, 2015, Volume: 38, Issue:11 Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome	2015
Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial. Diabetes care, 2015, Volume: 38, Issue:11 Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Myocardial Infarction; Osteoporotic Fractures; Risk Factors; Thiazolidinediones	2015
Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:2 Topics: Adamantane; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Dyslipidemias; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Mortality; Neoplasms; Risk Factors; Sex Factors; Smoking	2016
Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. The American journal of medicine, 2016, Volume: 129, Issue:3 Topics: Adamantane; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Incretins; Male; Middle Aged; Myocardial Infarction; Risk; Stroke	2016
Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial. Pharmacotherapy, 2015, Volume: 35, Issue:11 Topics: Acarbose; Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Monitoring, Ambulatory; Nitriles; Pyrrolidines; Vildagliptin	2015
A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes. Diabetes care, 2016, Volume: 39, Issue:4 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin; Whey Proteins	2016
Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea. Current medical research and opinion, 2016, Volume: 32, Issue:6 Topics: Adamantane; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin	2016
[New attempt in a benefit evaluation]. MMW Fortschritte der Medizin, 2015, Dec-14, Volume: 157, Issue:21-22 Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Metformin; Sulfonylurea Compounds	2015
Combination of Saxagliptin and Metformin Is Effective as Initial Therapy in New-Onset Type 2 Diabetes Mellitus With Severe Hyperglycemia. The Journal of clinical endocrinology and metabolism, 2016, Volume: 101, Issue:6 Topics: Adamantane; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Treatment Outcome	2016
Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist. Diabetes, 2016, Volume: 65, Issue:8 Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Healthy Volunteers; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Peptide Fragments; Pyrrolidines; Vildagliptin	2016
Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. Diabetes care, 2016, Volume: 39, Issue:8 Topics: Adamantane; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Female; Follow-Up Studies; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin, Short-Acting; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Renal Insufficiency; Risk Factors; Sulfonylurea Compounds	2016
Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:11 Topics: Adamantane; Aged; Combined Modality Therapy; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Diabetic; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Down-Regulation; Drug Administration Schedule; Drug Therapy, Combination; Exercise Therapy; Feedback, Physiological; Female; Glucagon-Like Peptide 1; Humans; Male; Meals; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Vildagliptin	2016
Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues. Diabetes research and clinical practice, 2016, Volume: 116 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nitriles; Pilot Projects; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin	2016
Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial. Diabetes research and clinical practice, 2016, Volume: 116 Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Prospective Studies; Renal Dialysis; Serum Albumin	2016
Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus. Endocrine journal, 2016, Aug-31, Volume: 63, Issue:8 Topics: Adamantane; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combination; Female; Humans; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Vildagliptin	2016
Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:11 Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections	2016
Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin. Journal of atherosclerosis and thrombosis, 2017, Feb-01, Volume: 24, Issue:2 Topics: Adamantane; Adult; Aged; Apolipoprotein B-48; Biomarkers; Blood Glucose; Cholesterol; Chylomicrons; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fasting; Female; Follow-Up Studies; Glycemic Index; Humans; Hypoglycemic Agents; Insulin; Lipoproteins; Male; Middle Aged; Nitriles; Postprandial Period; Prognosis; Pyrrolidines; Triglycerides; Vildagliptin; Young Adult	2017
One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:11 Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome	2016
Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION). Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:8 Topics: Adamantane; Aged; Asian People; Blood Glucose; Body Mass Index; China; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin	2016
Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride. Journal of diabetes investigation, 2017, Volume: 8, Issue:2 Topics: Adamantane; Cardiovascular Diseases; Chemokine CXCL12; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Risk Factors; Sulfonylurea Compounds; Vildagliptin	2017
Small Intestinal Glucose Delivery Affects the Lowering of Blood Glucose by Acute Vildagliptin in Type 2 Diabetes. The Journal of clinical endocrinology and metabolism, 2016, Volume: 101, Issue:12 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Duodenum; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Pyrrolidines; Vildagliptin	2016
Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial. Medicine, 2016, Volume: 95, Issue:43 Topics: Adamantane; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Injections, Intramuscular; Insulin; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult	2016
Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin. Clinical therapeutics, 2016, Volume: 38, Issue:12 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Risk Factors; Sulfonylurea Compounds; Treatment Outcome	2016
Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus. Endocrine journal, 2017, Feb-27, Volume: 64, Issue:2 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Glycated Hemoglobin; Humans; Male; Middle Aged; Nitriles; Piperidines; Pyrrolidines; Treatment Outcome; Uracil; Vildagliptin	2017
COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:3 Topics: Adamantane; Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2017
Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment. Diabetes research and clinical practice, 2017, Volume: 123 Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin	2017
Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose. Endocrine journal, 2017, Apr-29, Volume: 64, Issue:4 Topics: Adamantane; Adult; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Circadian Rhythm; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Substitution; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Time Factors; Vildagliptin	2017
Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study). Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:11 Topics: Acarbose; Adamantane; Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Dipeptides; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Male; Metformin; Middle Aged; Treatment Outcome	2017
Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2008, Volume: 40, Issue:12 Topics: Adamantane; Adult; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin	2008
Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes. International journal of clinical pharmacology and therapeutics, 2008, Volume: 46, Issue:7 Topics: Adamantane; Adult; Aged; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Vildagliptin	2008
Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:1 Topics: Adamantane; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Digestion; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nitriles; Placebos; Postprandial Period; Pyrrolidines; Satiety Response; Vildagliptin	2009
Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:1 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Islets of Langerhans; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin	2009
Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:3 Topics: Adamantane; Adipose Tissue; Adult; Aged; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Lipid Mobilization; Male; Middle Aged; Muscle, Skeletal; Nitriles; Norepinephrine; Oxidation-Reduction; Postprandial Period; Pyrrolidines; Vildagliptin	2009
Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes research and clinical practice, 2009, Volume: 83, Issue:2 Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Nitriles; Placebos; Pyrrolidines; Treatment Outcome; Vildagliptin; Young Adult	2009
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:2 Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Time Factors; Vildagliptin	2009
Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:4 Topics: Adamantane; Aged; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin	2009
Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2009, Volume: 41, Issue:5 Topics: Adamantane; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Young Adult	2009
Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:5 Topics: Adamantane; Adult; Aged; Americas; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin; Young Adult	2009
Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Current medical research and opinion, 2009, Volume: 25, Issue:5 Topics: Adamantane; Adult; Aged; Algorithms; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin	2009
Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:8 Topics: Adamantane; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Metformin; Nitriles; Pyrrolidines; Vildagliptin	2009
The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes care, 2009, Volume: 32, Issue:9 Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Treatment Outcome; Young Adult	2009
Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:6 Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Treatment Outcome; Vildagliptin; Weight Gain; Young Adult	2009
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:6 Topics: Adamantane; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Postprandial Period; Treatment Outcome	2009
Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. International journal of clinical practice, 2009, Volume: 63, Issue:9 Topics: Adamantane; Adolescent; Adult; Aged; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Middle Aged; Sulfonylurea Compounds; Treatment Outcome; Young Adult	2009
Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:10 Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Thiazolidinediones; Vildagliptin; Weight Gain; Young Adult	2009
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Current medical research and opinion, 2009, Volume: 25, Issue:10 Topics: Adamantane; Administration, Oral; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptides; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Treatment Outcome	2009
Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2009, Volume: 41, Issue:12 Topics: Adamantane; Demography; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Time Factors; Treatment Outcome; Vildagliptin	2009
Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation. European journal of endocrinology, 2009, Volume: 161, Issue:6 Topics: Adamantane; Cyclohexanes; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Nitriles; Phenylalanine; Pyrrolidines; Vildagliptin	2009
Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:12 Topics: Adamantane; Adolescent; Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Pancreatic Function Tests; Pioglitazone; Rosiglitazone; Thiazolidinediones; Young Adult	2009
Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes care, 2010, Volume: 33, Issue:4 Topics: Adamantane; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemic Agents; Metformin; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin	2010
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgraduate medicine, 2010, Volume: 122, Issue:3 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Risk; Stroke	2010
A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabetic medicine : a journal of the British Diabetic Association, 2010, Volume: 27, Issue:3 Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Young Adult	2010
Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. Diabetes research and clinical practice, 2010, Volume: 89, Issue:3 Topics: Adamantane; Aged; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin	2010
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2010, Volume: 42, Issue:9 Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Vildagliptin	2010
Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:8 Topics: Adamantane; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Treatment Outcome; Vildagliptin	2010
Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes. British journal of clinical pharmacology, 2010, Volume: 70, Issue:1 Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Time Factors; Treatment Outcome; Vildagliptin; Young Adult	2010
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:9 Topics: Adamantane; Adolescent; Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; Weight Gain; Young Adult	2010
Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Current medical research and opinion, 2010, Volume: 26, Issue:10 Topics: Adamantane; Administration, Oral; Adult; Aged; Blood Glucose; Circadian Rhythm; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Treatment Failure; Treatment Outcome	2010
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes/metabolism research and reviews, 2010, Volume: 26, Issue:7 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2010
Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. International journal of clinical practice, 2010, Volume: 64, Issue:12 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome	2010
Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes. International journal of clinical pharmacology and therapeutics, 2010, Volume: 48, Issue:9 Topics: Adamantane; Adult; Aged; Area Under Curve; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin	2010
Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:4 Topics: Adamantane; Administration, Oral; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucose; Humans; Incretins; Injections, Intravenous; Insulin; Insulin Secretion; Male; Middle Aged; Nitriles; Pyrrolidines; Up-Regulation; Vildagliptin	2011
Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:7 Topics: Adamantane; Adolescent; Adult; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Young Adult	2011
Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:6 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Kidney Failure, Chronic; Male; Middle Aged; Placebos; Treatment Outcome	2011
Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:6 Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Young Adult	2011
Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clinical pharmacokinetics, 2011, Volume: 50, Issue:4 Topics: Adamantane; Adult; Aged; Diabetes Mellitus, Type 2; Dialysis Solutions; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Half-Life; Hepatic Insufficiency; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Renal Dialysis; Renal Insufficiency; Severity of Illness Index	2011
Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia, 2011, Volume: 54, Issue:8 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin	2011
Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:9 Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Treatment Outcome	2011
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diabetes & vascular disease research, 2011, Volume: 8, Issue:2 Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Placebo Effect; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome; United States	2011
Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diabetes & vascular disease research, 2011, Volume: 8, Issue:2 Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Time Factors; Treatment Outcome	2011
The metabolic syndrome influences the response to incretin-based therapies. Acta diabetologica, 2011, Volume: 48, Issue:3 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Male; Metabolic Syndrome; Middle Aged; Nitriles; Peptides; Prognosis; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin	2011
Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. Postgraduate medicine, 2011, Volume: 123, Issue:4 Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Thiazolidinediones; United States; Young Adult	2011
Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:10 Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Kidney Failure, Chronic; Male; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin; Young Adult	2011
Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes care, 2011, Volume: 34, Issue:9 Topics: Adamantane; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vasodilation; Vildagliptin	2011
Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes research and clinical practice, 2011, Volume: 94, Issue:2 Topics: Adamantane; Adult; Aged; Analysis of Variance; Asia; Asian People; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Time Factors; Treatment Outcome	2011
The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocrine journal, 2011, Volume: 58, Issue:11 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Renal Dialysis; Statistics, Nonparametric; Vildagliptin	2011
Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. International journal of clinical practice, 2011, Volume: 65, Issue:12 Topics: Adamantane; Aged; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Double-Blind Method; Fasting; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney Failure, Chronic; Treatment Outcome	2011
Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden. Primary care diabetes, 2012, Volume: 6, Issue:2 Topics: Adamantane; Biomarkers; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Sulfonylurea Compounds; Sweden; Time Factors; Treatment Outcome	2012
Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. Journal of diabetes, 2012, Volume: 4, Issue:2 Topics: Adamantane; Aged; Alkaline Phosphatase; Biomarkers; Blood Glucose; Bone and Bones; Bone Resorption; Calcium; Collagen Type I; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Homeostasis; Humans; Insulin; Male; Middle Aged; Netherlands; Nitriles; Peptides; Phosphates; Postprandial Period; Pyrrolidines; Time Factors; Treatment Outcome; Vildagliptin	2012
Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes/metabolism research and reviews, 2012, Volume: 28, Issue:3 Topics: Adamantane; Adult; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Placebos	2012
The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. American heart journal, 2011, Volume: 162, Issue:5 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; France; Humans; Israel; Male; Middle Aged; Myocardial Infarction; Research Design; Survival Analysis; Treatment Outcome; United States	2011
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. Journal of clinical pharmacology, 2012, Volume: 52, Issue:10 Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2012
Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:4 Topics: Adamantane; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Latin America; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Postprandial Period; Treatment Outcome; United States	2012
Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Current medical research and opinion, 2012, Volume: 28, Issue:4 Topics: Adamantane; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged	2012
Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:8 Topics: Adamantane; Adolescent; Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Young Adult	2012
Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. British journal of clinical pharmacology, 2012, Volume: 73, Issue:3 Topics: Adamantane; Administration, Oral; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Glucagon-Like Peptide 1; Humans; Insulin; Male; Middle Aged; Models, Biological; Nitriles; Pyrrolidines; Vildagliptin	2012
Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. British journal of clinical pharmacology, 2012, Volume: 73, Issue:3 Topics: Adamantane; Administration, Oral; Adult; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Half-Life; Humans; Male; Middle Aged; Models, Biological; Nitriles; Pyrrolidines; Vildagliptin	2012
Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes. International journal of clinical pharmacology and therapeutics, 2012, Volume: 50, Issue:4 Topics: Adamantane; Adult; Analysis of Variance; Area Under Curve; Asian People; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Monitoring; Eating; Feeding Behavior; Female; Food-Drug Interactions; Glucagon-Like Peptide 1; Humans; Intestinal Absorption; Japan; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Treatment Outcome; Vildagliptin	2012
Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes technology & therapeutics, 2012, Volume: 14, Issue:6 Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Weight Loss	2012
Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease. Cardiovascular diabetology, 2012, Jun-06, Volume: 11 Topics: Adamantane; Adiponectin; Atherosclerosis; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Humans; Hypoglycemic Agents; Inflammation; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Israel; Matrix Metalloproteinase 9; Metformin; Nitriles; Platelet Function Tests; Prospective Studies; Pyrrolidines; Research Design; Thrombosis; Time Factors; Treatment Outcome; Vildagliptin	2012
Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes care, 2012, Volume: 35, Issue:10 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Inflammation; Interleukin-18; Interleukin-6; Male; Metformin; Middle Aged; Nitriles; Oxidative Stress; Postprandial Period; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2012
One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:11 Topics: Adamantane; Aged; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Male; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin	2012
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose? Diabetes technology & therapeutics, 2012, Volume: 14, Issue:10 Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin	2012
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes & metabolism, 2012, Volume: 38, Issue:4 Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; France; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pilot Projects; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin; Young Adult	2012
Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovascular diabetology, 2012, Aug-06, Volume: 11 Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; C-Peptide; Cross-Over Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Japan; Male; Middle Aged; Monitoring, Ambulatory; Natriuretic Peptide, Brain; Nitriles; Pilot Projects; Plasminogen Activator Inhibitor 1; Postprandial Period; Predictive Value of Tests; Pyrazines; Pyrrolidines; Serum Albumin; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin	2012
Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. Current medical research and opinion, 2012, Volume: 28, Issue:10 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Tolerance; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged	2012
Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:3 Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Asia; Australia; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; United States; Vildagliptin	2013
Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:18 Topics: Adamantane; Adult; Chemokines; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Down-Regulation; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Intention to Treat Analysis; Intercellular Signaling Peptides and Proteins; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Resistin; Retinol-Binding Proteins, Plasma; Vildagliptin	2012
Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes. Experimental diabetes research, 2012, Volume: 2012 Topics: Adamantane; Aged; Aged, 80 and over; Capillaries; Chronic Disease; Diabetes Mellitus, Type 2; Diabetic Foot; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Gene Expression Regulation; Glucagon-Like Peptide 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Italy; Male; Middle Aged; Neovascularization, Physiologic; Nitriles; Oxidative Stress; Proteasome Endopeptidase Complex; Pyrrolidines; RNA, Messenger; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Vildagliptin; Wound Healing	2012
The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2013, Volume: 30, Issue:6 Topics: Adamantane; Biomarkers; Chylomicron Remnants; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hyperglycemia; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Meals; Nitriles; Particle Size; Postprandial Period; Pyrrolidines; Triglycerides; Vildagliptin	2013
Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis, 2013, Volume: 227, Issue:2 Topics: Adamantane; Atherosclerosis; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cytokines; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Inflammation; Nitriles; Oxidative Stress; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Tyrosine; Vildagliptin	2013
Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vascular health and risk management, 2013, Volume: 9 Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Body Weight; Chi-Square Distribution; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Kidney; Male; Middle Aged; Nitriles; Pyrrolidines; Severity of Illness Index; Time Factors; Treatment Outcome; Vildagliptin	2013
Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:6 Topics: Adamantane; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Nitriles; Postprandial Period; Proinsulin; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin	2013
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:5 Topics: Adamantane; Aged; Blood Glucose; Body Weight; Circadian Rhythm; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Eating; Enzyme Inhibitors; Female; Glucagon; Glycated Hemoglobin; Humans; Insulin; Lipids; Male; Middle Aged; Pyrrolidines	2004
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes care, 2004, Volume: 27, Issue:12 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Double-Blind Method; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Placebos; Protease Inhibitors; Pyrrolidines	2004
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:8 Topics: Adamantane; Adenosine Deaminase Inhibitors; Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Female; Glycoproteins; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Models, Biological; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin	2005
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes, obesity & metabolism, 2005, Volume: 7, Issue:6 Topics: Adamantane; Adenosine Deaminase Inhibitors; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin	2005
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia, 2006, Volume: 49, Issue:9 Topics: Adamantane; Apolipoprotein B-48; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Intestinal Mucosa; Intestines; Lipids; Lipoproteins; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Time Factors; Treatment Outcome; Triglycerides; Vildagliptin	2006
Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2006, Volume: 38, Issue:6 Topics: Adamantane; Adenosine Deaminase Inhibitors; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Double-Blind Method; Female; Glycated Hemoglobin; Glycoproteins; Humans; Male; Middle Aged; Nitriles; Placebos; Protease Inhibitors; Pyrrolidines; Vildagliptin	2006
Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes. Journal of clinical pharmacology, 2007, Volume: 47, Issue:1 Topics: Adamantane; Adult; Analysis of Variance; Blood Glucose; C-Peptide; Chromatography, Liquid; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Radioimmunoassay; Tandem Mass Spectrometry; Time Factors; Vildagliptin	2007
Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes research and clinical practice, 2007, Volume: 76, Issue:1 Topics: Adamantane; Administration, Oral; Adult; Asian People; Black People; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fasting; Female; Glycated Hemoglobin; Hispanic or Latino; Humans; Hypoglycemic Agents; Kinetics; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; White People	2007
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:4 Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Enzyme Inhibitors; Female; Glucose; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Islets of Langerhans; Kinetics; Male; Middle Aged; Nitriles; Obesity; Pyrrolidines; Vildagliptin	2007
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes care, 2007, Volume: 30, Issue:2 Topics: Adamantane; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Edema; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Racial Groups; Rosiglitazone; Thiazolidinediones; Vildagliptin	2007
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes care, 2007, Volume: 30, Issue:4 Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin	2007
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:2 Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Ligands; Lipids; Male; Middle Aged; Nitriles; Pioglitazone; Proinsulin; Protease Inhibitors; Pyrrolidines; Thiazolidinediones; Treatment Failure; Treatment Outcome; Vildagliptin	2007
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:2 Topics: Adamantane; Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Nitriles; Pioglitazone; Protease Inhibitors; Pyrrolidines; Thiazolidinediones; Treatment Outcome; Vildagliptin	2007
Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2007, Volume: 39, Issue:3 Topics: Adamantane; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Fasting; Female; Glycated Hemoglobin; Hemoglobins; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Nitriles; Placebos; Pyrrolidines; Time Factors; Treatment Outcome; Vildagliptin	2007
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia, 2007, Volume: 50, Issue:6 Topics: Adamantane; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Placebos; Pyrrolidines; Vildagliptin	2007
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. Journal of clinical pharmacology, 2007, Volume: 47, Issue:5 Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycoproteins; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin	2007
Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2007, Volume: 24, Issue:9 Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; United Kingdom; Vildagliptin	2007
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clinical pharmacokinetics, 2007, Volume: 46, Issue:7 Topics: Adamantane; Administration, Oral; Adult; Aged; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Half-Life; Humans; Hypoglycemic Agents; Male; Middle Aged; Nausea; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin; Vomiting	2007
Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes care, 2007, Volume: 30, Issue:12 Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Nitriles; Pyrrolidines; Safety; Vildagliptin	2007
Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia. The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:1 Topics: Adamantane; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Models, Biological; Nitriles; Pyrrolidines; Vildagliptin	2008
Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2007, Volume: 39, Issue:11 Topics: Adamantane; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Proinsulin; Pyrrolidines; Treatment Outcome; Vildagliptin	2007
Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:1 Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Treatment Outcome; Vildagliptin	2008
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:2 Topics: Adamantane; Blood Glucose; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Islets of Langerhans; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin	2008
Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:8* Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Treatment Outcome; Vildagliptin	2008
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:11 Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin	2008
The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clinical endocrinology, 2008, Volume: 69, Issue:5 Topics: Adamantane; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drinking; Eating; Enteroendocrine Cells; Fasting; Gastric Emptying; Ghrelin; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Middle Aged; Nitriles; Organ Size; Placebos; Postprandial Period; Pyrrolidines; Satiation; Stomach; Vildagliptin	2008
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetic medicine : a journal of the British Diabetic Association, 2008, Volume: 25, Issue:4 Topics: Acarbose; Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin	2008
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:5 Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome	2008
Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:11 Topics: Adamantane; Adult; Analysis of Variance; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Insulin; Lipids; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Time Factors; Vildagliptin	2008
Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2008, Volume: 40, Issue:6 Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Longitudinal Studies; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin	2008
Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. Current medical research and opinion, 2008, Volume: 24, Issue:6 Topics: Adamantane; Adolescent; Adult; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Female; Food-Drug Interactions; Humans; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin	2008

Other Studies

234 other study(ies) available for adamantane and Diabetes Mellitus, Adult-Onset

Article	Year
Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China. Frontiers in endocrinology, 2021, Volume: 12 Topics: Adamantane; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Humans; Linagliptin; Metformin; Middle Aged; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil; Vildagliptin	2021
Efficacy of vildagliptin on 10-year cardiovascular risk reduction in Thai patients with type 2 diabetes mellitus: A real-world observational study. Diabetes & metabolic syndrome, 2022, Volume: 16, Issue:3 Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Nitriles; Risk Factors; Thailand; Treatment Outcome; Vildagliptin	2022
ZD-2, a novel DPP4 inhibitor, protects islet β-cell and improves glycemic control in high-fat-diet-induced obese mice. Life sciences, 2022, Jun-01, Volume: 298 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Glycemic Control; Hormones; Hypoglycemic Agents; Mice; Mice, Obese; Nitriles; Pyrrolidines; Vildagliptin	2022
[Saxagliptin alleviates kidney injury in diabetic rats by down-regulating the expression of mammalian target of rapamycin (mTOR)]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2022, Volume: 38, Issue:5 Topics: Adamantane; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptides; Interleukin-1; Interleukin-6; Kidney; Male; Mammals; Rats; Sirolimus; TOR Serine-Threonine Kinases; Tumor Necrosis Factor-alpha	2022
Variation in open access vildagliptin use in Waikato patients with type 2 diabetes. The New Zealand medical journal, 2022, 01-21, Volume: 135, Issue:1548 Topics: Access to Information; Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; New Zealand; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin	2022
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 11-05, Volume: 140, Issue:19 Topics: Adamantane; Aged; Benzhydryl Compounds; Clinical Decision-Making; Decision Support Techniques; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Health Status; Heart Failure; Humans; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome	2019
Saxagliptin attenuates glomerular podocyte injury by increasing the expression of renal nephrin and podocin in type 2 diabetic rats. Acta diabetologica, 2020, Volume: 57, Issue:3 Topics: Adamantane; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Glycated Hemoglobin; Humans; Intracellular Signaling Peptides and Proteins; Kidney; Male; Membrane Proteins; p38 Mitogen-Activated Protein Kinases; Podocytes; Rats; Rats, Sprague-Dawley	2020
Saxagliptin protects against hypoxia-induced damage in H9c2 cells. Chemico-biological interactions, 2020, Jan-05, Volume: 315 Topics: Adamantane; Animals; Apoptosis; Cell Line; Cell Survival; Cytokines; Diabetes Mellitus, Type 2; Dipeptides; Endothelial Cells; Heme Oxygenase-1; HMGB1 Protein; Hypoxia; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myeloid Differentiation Factor 88; Myocytes, Cardiac; NADPH Oxidase 4; NF-E2-Related Factor 2; Oxidative Stress; Protective Agents; Rats; Signal Transduction	2020
Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan. The Journal of dermatology, 2020, Volume: 47, Issue:3 Topics: Adamantane; Adult; Age Factors; Aged; Case-Control Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Incidence; Linagliptin; Male; Middle Aged; Pemphigoid, Bullous; Piperidines; Risk Factors; Sitagliptin Phosphate; Taiwan; Uracil; Vildagliptin; Young Adult	2020
Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2020, Volume: 37, Issue:5 Topics: Adamantane; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incidence; Incretins; Linagliptin; Liraglutide; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Risk Factors; Sitagliptin Phosphate; Smoking	2020
Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus. Applied health economics and health policy, 2021, Volume: 19, Issue:1 Topics: Adamantane; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Glucosides; Humans; Metformin; Prospective Studies; Randomized Controlled Trials as Topic	2021
Saxagliptin and vildagliptin lowered albuminuria in patients with diabetes and hypertension independent on glycaemic control. International journal of clinical practice, 2021, Volume: 75, Issue:3 Topics: Adamantane; Albuminuria; Animals; Diabetes Mellitus, Type 2; Dipeptides; Glycemic Control; Humans; Hypertension; Rats; Vildagliptin	2021
A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment. Life sciences, 2021, Jun-01, Volume: 274 Topics: Acarbose; Adamantane; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Male; Middle Aged; Prognosis; Vildagliptin	2021
Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial. Journal of the American College of Cardiology, 2021, 04-13, Volume: 77, Issue:14 Topics: Adamantane; Aged; Biomarkers; Cause of Death; Coronary Artery Disease; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Disease Risk Factors; Humans; Male; Mortality; Risk Assessment	2021
Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro. Fundamental & clinical pharmacology, 2022, Volume: 36, Issue:1 Topics: Adamantane; Chromatography, Liquid; Cytochrome P-450 CYP3A; Diabetes Mellitus, Type 2; Dipeptides; Humans; Tandem Mass Spectrometry	2022
Vitamin D3 potentiates the nephroprotective effects of vildagliptin-metformin combination in a rat model of metabolic syndrome. Fundamental & clinical pharmacology, 2022, Volume: 36, Issue:2 Topics: Adamantane; Animals; Cholecalciferol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin	2022
Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study. Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:10 Topics: Adamantane; Adult; Aged; Cardiotoxicity; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Europe; Female; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Vildagliptin	2017
Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting. Journal of diabetes, 2018, Volume: 10, Issue:1 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Treatment Outcome; Vildagliptin	2018
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovascular drugs and therapy, 2017, Volume: 31, Issue:2 Topics: Adamantane; AMP-Activated Protein Kinases; Animals; Apoptosis; Benzhydryl Compounds; CARD Signaling Adaptor Proteins; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Fibroblasts; Fibrosis; Glucosides; Hypoglycemic Agents; Inflammasomes; Inflammation Mediators; Kidney Tubules, Proximal; Male; Mice, Inbred C57BL; Mice, Obese; Myocytes, Cardiac; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Ventricular Function, Left	2017
Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. Diabetes research and clinical practice, 2017, Volume: 130 Topics: Adamantane; Adolescent; Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Hospitalization; Humans; Hypoglycemia; Male; Middle Aged; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult	2017
Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity and Intima-Media Thickness in Type 2 Diabetic Patients. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2017, Volume: 24, Issue:4 Topics: Adamantane; Biomarkers; Blood Glucose; Carotid Arteries; Carotid Intima-Media Thickness; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Predictive Value of Tests; Prospective Studies; Pulse Wave Analysis; Recovery of Function; Time Factors; Treatment Outcome; Vascular Stiffness	2017
Healthcare costs among adults with type 2 diabetes initiating saxagliptin or linagliptin: a US-based claims analysis. Current medical research and opinion, 2017, Volume: 33, Issue:10 Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptides; Female; Health Care Costs; Humans; Hypoglycemic Agents; Insurance Claim Review; Linagliptin; Male; Middle Aged; Retrospective Studies; United States	2017
Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio. The Annals of pharmacotherapy, 2017, Volume: 51, Issue:7 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Hospitalization; Humans; Piperidines; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Sitagliptin Phosphate; Uracil	2017
Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients. European journal of clinical investigation, 2017, Volume: 47, Issue:11 Topics: Adamantane; Adipose Tissue; Adult; Aged; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Vildagliptin	2017
Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats. PloS one, 2017, Volume: 12, Issue:10 Topics: Adamantane; Administration, Oral; Animals; Blood Glucose; Butyrates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Insulin Resistance; Interleukin-6; Male; Nitriles; Pyrrolidines; Random Allocation; Rats, Sprague-Dawley; RNA, Ribosomal, 16S; Vildagliptin	2017
Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study). Journal of diabetes research, 2017, Volume: 2017 Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Chi-Square Distribution; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Logistic Models; Male; Metformin; Middle Aged; Multivariate Analysis; Nitriles; Pyrrolidines; Republic of Korea; Retrospective Studies; Time Factors; Treatment Outcome; Vildagliptin	2017
Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α Diabetes care, 2017, Volume: 40, Issue:11 Topics: Adamantane; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Natriuresis	2017
Response to Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α Diabetes care, 2017, Volume: 40, Issue:11 Topics: Adamantane; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Natriuresis	2017
Vildagliptin-induced acute pancreatitis without enzyme elevation. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2017, Volume: 28, Issue:6 Topics: Abdominal Pain; Acute Disease; Adamantane; Aged; Amylases; Diabetes Mellitus, Type 2; Diagnosis, Differential; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Lipase; Male; Middle Aged; Nitriles; Pancreatitis; Pyrrolidines; Vildagliptin	2017
Vildagliptin loaded triangular DNA nanospheres coated with eudragit for oral delivery and better glycemic control in type 2 diabetes mellitus. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 97 Topics: Adamantane; Administration, Oral; Animals; Blood Glucose; Crystallization; Delayed-Action Preparations; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; DNA; Drug Carriers; Drug Delivery Systems; Drug Liberation; Hypoglycemic Agents; Male; Mice; Nanospheres; Nanotechnology; Nitriles; Particle Size; Polymethacrylic Acids; Pyrrolidines; Vildagliptin	2018
Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease. Current medical research and opinion, 2018, Volume: 34, Issue:6 Topics: Adamantane; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Sitagliptin Phosphate	2018
Dipeptidyl Peptidase-4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study. Pharmacotherapy, 2018, Volume: 38, Issue:3 Topics: Adamantane; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Retrospective Studies; Veterans	2018
Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy. Biological & pharmaceutical bulletin, 2018, Volume: 41, Issue:2 Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Exenatide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Ligands; Liraglutide; Models, Molecular; Molecular Targeted Therapy; Nitriles; Peptides; Piperidines; Pyrrolidines; Reproducibility of Results; Sitagliptin Phosphate; Uracil; Venoms; Vildagliptin	2018
Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes. Diabetes research and clinical practice, 2018, Volume: 138 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin	2018
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. Cardiovascular drugs and therapy, 2018, Volume: 32, Issue:2 Topics: Adamantane; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Glucosides; Inflammasomes; Inflammation Mediators; Kidney; Male; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2018
Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes. The Medical letter on drugs and therapeutics, 2018, 03-26, Volume: 60, Issue:1543 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2018
Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients. Pharmacoepidemiology and drug safety, 2018, Volume: 27, Issue:6 Topics: Adamantane; Administration, Oral; Adverse Drug Reaction Reporting Systems; Aged; Bayes Theorem; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Humans; Linagliptin; Male; Middle Aged; Piperidines; Practice Guidelines as Topic; Sitagliptin Phosphate; United States; United States Food and Drug Administration; Uracil	2018
Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings . International journal of clinical pharmacology and therapeutics, 2018, Volume: 56, Issue:9 Topics: Adamantane; Adult; Age Factors; Aged; Biomarkers; Blood Glucose; Clinical Decision-Making; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Germany; Humans; Male; Middle Aged; Patient Selection; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Sex Factors; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Vildagliptin	2018
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data. Revista da Associacao Medica Brasileira (1992), 2019, Volume: 65, Issue:1 Topics: Adamantane; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phosphatidylcholines; Sulfonylurea Compounds; Treatment Outcome	2019
SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease. The lancet. Diabetes & endocrinology, 2019, Volume: 7, Issue:6 Topics: Adamantane; Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Glucosides; Humans; Incretins; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2	2019
DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice. Clinical therapeutics, 2019, Volume: 41, Issue:8 Topics: Adamantane; Aged; Aged, 80 and over; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; General Practice; Humans; Male; Middle Aged; Sitagliptin Phosphate; United Kingdom	2019
Effect of Saxagliptin on Endothelial Function in Patients with Type 2 Diabetes: A Prospective Multicenter Study. Scientific reports, 2019, 07-15, Volume: 9, Issue:1 Topics: Adamantane; Aged; Blood Glucose; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Endothelial Cells; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Prospective Studies; Vasodilation	2019
A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. JAMA dermatology, 2013, Volume: 149, Issue:2 Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Male; Middle Aged; Nitriles; Pemphigoid, Bullous; Pyrrolidines; Severity of Illness Index; Vildagliptin	2013
Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization. Advances in therapy, 2013, Volume: 30, Issue:2 Topics: Adamantane; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Combinations; Efficiency; Employment; Female; Health Care Costs; Health Services; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Nitriles; Patient Satisfaction; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin	2013
Saxagliptin + metformin. Mostly disadvantages. Prescrire international, 2013, Volume: 22, Issue:135 Topics: Adamantane; Administration, Oral; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Tablets; Treatment Outcome	2013
DPP4 inhibitor-induced polyarthritis: a report of three cases. Rheumatology international, 2014, Volume: 34, Issue:2 Topics: Adamantane; Arthritis; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin	2014
Discovery of SAR184841, a potent and long-lasting inhibitor of 11β-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D. Bioorganic & medicinal chemistry letters, 2013, Apr-15, Volume: 23, Issue:8 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Mice; Mice, Transgenic; Structure-Activity Relationship	2013
DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. The Journal of endocrinology, 2013, Volume: 218, Issue:1 Topics: Adamantane; Animals; Behavior, Animal; Brain; Cognition Disorders; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Insulin Resistance; Male; Maze Learning; Memory; Memory Disorders; Mitochondria; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation. Drug design, development and therapy, 2013, Volume: 7 Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Heart Transplantation; Humans; Immunosuppressive Agents; Lipids; Male; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Vildagliptin	2013
Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model. Diabetologia, 2013, Volume: 56, Issue:8 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Female; Immunohistochemistry; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Nitriles; Obesity; Pyrrolidines; Vildagliptin	2013
Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan. Current medical research and opinion, 2013, Volume: 29, Issue:7 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fasting; Female; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Medication Adherence; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin	2013
Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082. Diabetes care, 2013, Volume: 36, Issue:6 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Nitriles; Pyrazines; Pyrrolidines; Triazoles	2013
Individualising treatment for older people with diabetes. Lancet (London, England), 2013, Aug-03, Volume: 382, Issue:9890 Topics: Adamantane; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Nitriles; Pyrrolidines; Vildagliptin	2013
Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes. Journal of Korean medical science, 2013, Volume: 28, Issue:6 Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Insulin Resistance; Male; Middle Aged; Multivariate Analysis; Nitriles; Pyrazines; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
The effects of dipeptidyl-peptidase-IV inhibitor, vildagliptin, on the exocrine pancreas in spontaneously diabetic Goto-Kakizaki rats. Pancreas, 2013, Volume: 42, Issue:5 Topics: Acinar Cells; Adamantane; Animals; Apoptosis; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Glucagon-Like Peptide 1; Immunohistochemistry; Insulin; Ki-67 Antigen; Male; Nitriles; Pancreas, Exocrine; Pancreatic Ducts; Pyrrolidines; Rats; Rats, Wistar; Species Specificity; Vildagliptin	2013
Predictors of medication adherence in patients with type 2 diabetes mellitus. Current medical research and opinion, 2013, Volume: 29, Issue:10 Topics: Adamantane; Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Models, Biological; Patient Compliance; Sulfonylurea Compounds; Thiazolidinediones	2013
Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors. Prescrire international, 2013, Volume: 22, Issue:138 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glyburide; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Vildagliptin	2013
Commentary. Diabetes/metabolism research and reviews, 2013, Volume: 29, Issue:5 Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male	2013
Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes. Endocrine, metabolic & immune disorders drug targets, 2013, Volume: 13, Issue:3 Topics: Adamantane; Aged; Aged, 80 and over; Cognition; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Nitriles; Prospective Studies; Pyrrolidines; Vildagliptin	2013
Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study. Journal of diabetes, 2014, Volume: 6, Issue:3 Topics: Adamantane; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; India; Metformin; Nitriles; Obesity; Postprandial Period; Pyrrolidines; Retrospective Studies; Treatment Outcome; Vildagliptin	2014
Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). International journal of clinical practice, 2013, Volume: 67, Issue:10 Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Vildagliptin	2013
The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study. International journal of clinical practice, 2013, Volume: 67, Issue:10 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Medication Adherence; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin; Weight Loss	2013
Diabetes: Cardiovascular safety of 'gliptin' therapy. Nature reviews. Cardiology, 2013, Volume: 10, Issue:11 Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil	2013
Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus. Nature reviews. Endocrinology, 2013, Volume: 9, Issue:11 Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil	2013
Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat. Current vascular pharmacology, 2014, Volume: 12, Issue:6 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Kidney; Male; Nitriles; Proteinuria; Pyrrolidines; Random Allocation; Rats; Rats, Zucker; Renal Circulation; Sclerosis; Vasoconstriction; Vildagliptin	2014
Ramadan: type 2 diabetes and risk of hypoglycaemia. International journal of clinical practice, 2013, Volume: 67, Issue:10 Topics: Adamantane; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hypoglycemic Agents; Islam; Male; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin	2013
Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats. Ophthalmic research, 2013, Volume: 50, Issue:4 Topics: Adamantane; Administration, Oral; Analysis of Variance; Animals; Biomarkers; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression Profiling; Male; Nitriles; Obesity; Pyrrolidines; Rats; Real-Time Polymerase Chain Reaction; Retina; Vildagliptin	2013
Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice. Biochemical and biophysical research communications, 2013, Nov-01, Volume: 440, Issue:4 Topics: 1-Deoxynojirimycin; Adamantane; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucose Tolerance Test; Hypoglycemic Agents; Islets of Langerhans; Male; Mice; Mice, Inbred Strains; Nitriles; Pyrrolidines; Vildagliptin	2013
New drugs improve glycemic control in type 2 diabetes, but improving heart health remains elusive. JAMA, 2013, Oct-09, Volume: 310, Issue:14 Topics: Adamantane; Blood Glucose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Drug Approval; Humans; Hypoglycemic Agents; Piperidines; Uracil	2013
Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes. Cardiovascular diabetology, 2013, Nov-04, Volume: 12 Topics: Adamantane; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Homeodomain Proteins; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Nitriles; Phlorhizin; Pyrrolidines; Tetrazoles; Trans-Activators; Valine; Valsartan; Vildagliptin	2013
Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial. Cardiovascular journal of Africa, 2013, Volume: 24, Issue:7 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Diseases; Humans; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome	2013
The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:6 Topics: Adamantane; Adaptive Immunity; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Immunity, Innate; Mice; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; T-Lymphocytes; Triazoles; Vildagliptin	2014
Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany. Current medical research and opinion, 2014, Volume: 30, Issue:5 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Germany; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin	2014
Optimization of brain penetrant 11β-hydroxysteroid dehydrogenase type I inhibitors and in vivo testing in diet-induced obese mice. Journal of medicinal chemistry, 2014, Feb-13, Volume: 57, Issue:3 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Animals; Blood Glucose; Body Weight; Brain; Crystallography, X-Ray; Cyclopropanes; Diabetes Mellitus, Type 2; Dietary Fats; Humans; Hypoglycemic Agents; Insulin; Isoenzymes; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Obese; Models, Molecular; Pyrazoles; Rats; Stereoisomerism; Structure-Activity Relationship; Thiazoles	2014
ACP Journal Club. In at-risk patients with type 2 diabetes, saxagliptin and placebo did not differ for CV events. Annals of internal medicine, 2014, Jan-21, Volume: 160, Issue:2 Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male	2014
[Not Available]. Vnitrni lekarstvi, 2013, Volume: 59, Issue:12 Topics: Adamantane; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Nitriles; Pyrrolidines; Vildagliptin	2013
Saxagliptin, alogliptin, and cardiovascular outcomes. The New England journal of medicine, 2014, 01-30, Volume: 370, Issue:5 Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male	2014
Saxagliptin, alogliptin, and cardiovascular outcomes. The New England journal of medicine, 2014, 01-30, Volume: 370, Issue:5 Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil	2014
Hypoglycemia, its implications in clinical practice, and possible ways to prevent it. Current medical research and opinion, 2014, Volume: 30, Issue:5 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Female; Glipizide; Humans; Hypoglycemia; Male; Metformin	2014
Adding a DPP-4 inhibitor to metformin therapy may be safer than you think. Current medical research and opinion, 2014, Volume: 30, Issue:5 Topics: Adamantane; Diabetes Mellitus, Type 2; Female; Humans; Male; Metformin; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin	2014
No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations. Metabolic syndrome and related disorders, 2014, Volume: 12, Issue:3 Topics: Adamantane; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Multicenter Studies as Topic	2014
Outcome results renew debate about diabetes drug development. The lancet. Diabetes & endocrinology, 2013, Volume: 1, Issue:3 Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug Approval; Humans; Hypoglycemic Agents; Piperidines; Treatment Outcome; Uracil	2013
In AF or VTE, warfarin dosing by genotype improved time in therapeutic range but not clinical outcomes. Annals of internal medicine, 2014, Mar-18, Volume: 160, Issue:6 Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male	2014
Gliptins - do they increase cardiovascular risk or benefit? Expert opinion on drug safety, 2014, Volume: 13, Issue:5 Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil	2014
Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective. Journal of medical economics, 2014, Volume: 17, Issue:7 Topics: Adamantane; Computer Simulation; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Economic; Nitriles; Portugal; Prospective Studies; Pyrrolidines; Quality-Adjusted Life Years; Risk Factors; Sulfonylurea Compounds; Vildagliptin	2014
Between reduction of glucose fluctuations and increased therapeutic adherence: an example of the benefits of vildagliptin in an elderly diabetic patient. Aging clinical and experimental research, 2015, Volume: 27, Issue:1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Medication Adherence; Nitriles; Pyrrolidines; Vildagliptin	2015
Is there an impact of treatment with DPP-4 inhibitors on lymphocyte subpopulations in type 2 diabetic patients? Endokrynologia Polska, 2014, Volume: 65, Issue:2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Lymphocyte Subsets; Male; Middle Aged; Nitriles; Pyrrolidines; Random Allocation; Sitagliptin Phosphate; Vildagliptin	2014
Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE): post-hoc subanalysis of the Belgian data. Acta clinica Belgica, 2014, Volume: 69, Issue:3 Topics: Adamantane; Administration, Oral; Aged; Belgium; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin	2014
Comparative effectiveness of vildagliptin in combination with other oral anti-diabetes agents in usual-care conditions: the EDGE-Latin America study. Current medical research and opinion, 2014, Volume: 30, Issue:9 Topics: Adamantane; Administration, Oral; Adult; Aged; Biomarkers; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Latin America; Male; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin	2014
The dipeptidyl peptidase-4 inhibitor saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients. Cardiovascular diabetology, 2014, May-14, Volume: 13 Topics: Adamantane; Animals; Cell Movement; Cells, Cultured; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Human Umbilical Vein Endothelial Cells; Humans; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Neovascularization, Physiologic	2014
Saxagliptin-induced recurrent acute pancreatitis. Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:12 Topics: Acute Disease; Adamantane; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Pancreatitis; Recurrence	2014
Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. Diabetologia, 2014, Volume: 57, Issue:9 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; Glucose; Humans; Immunohistochemistry; Insulin; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Nitriles; Pyrrolidines; Vildagliptin	2014
[Therapeutic effect of saxagliptin in rat models of nonalcoholic fatty liver and type 2 diabetes]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2014, Volume: 34, Issue:6 Topics: Adamantane; Animals; bcl-2-Associated X Protein; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Disease Models, Animal; Hepatocytes; Insulin Resistance; Lipids; Liver; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley	2014
[New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR Der Internist, 2014, Volume: 55, Issue:7 Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil	2014
Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly. Drug design, development and therapy, 2014, Volume: 8 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Nitriles; Pyrrolidines; Retrospective Studies; Vildagliptin	2014
Cardioprotection by controlling hyperamylinemia in a "humanized" diabetic rat model. Journal of the American Heart Association, 2014, Aug-21, Volume: 3, Issue:4 Topics: Adamantane; Animals; Animals, Genetically Modified; Calcium; Cardiomegaly; Diabetes Mellitus, Type 2; Disease Models, Animal; Eicosanoids; Epoxide Hydrolases; Heart; Humans; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Myocardium; Myocytes, Cardiac; Obesity; Oxidative Stress; Pancreas; Prediabetic State; Rats; Sarcolemma; Urea	2014
Diabetes medications and heart failure: recognizing the risk. Circulation, 2014, Oct-28, Volume: 130, Issue:18 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Female; Heart Failure; Humans; Male	2014
Vildagliptin in patients with type 2 diabetes mellitus and renal impairment. Diabetes research and clinical practice, 2014, Volume: 106, Issue:2 Topics: Adamantane; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Male; Nitriles; Pyrrolidines; Renal Insufficiency; Vildagliptin	2014
Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism: clinical and experimental, 2015, Volume: 64, Issue:2 Topics: Activating Transcription Factor 4; Adamantane; Animals; Apoptosis; Caspase 3; Cell Cycle Proteins; Cell Nucleus; Cell Proliferation; Cell Survival; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Endoplasmic Reticulum Stress; Hyperglycemia; Insulin; Insulin-Secreting Cells; Male; Mice, Mutant Strains; Nitriles; Pyrrolidines; Random Allocation; Transcription Factor CHOP; Vildagliptin	2015
Saxagliptin restores vascular mitochondrial exercise response in the Goto-Kakizaki rat. Journal of cardiovascular pharmacology, 2015, Volume: 65, Issue:2 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glucagon-Like Peptide 1; Mitochondria, Muscle; Mitochondrial Proteins; Motor Activity; Muscle, Smooth, Vascular; Nitric Oxide Synthase Type III; Organelle Biogenesis; Physical Conditioning, Animal; Rats; Treatment Outcome	2015
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2014, Volume: 24, Issue:12 Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2014
[Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics]. MMW Fortschritte der Medizin, 2014, Jul-24, Volume: 156, Issue:13 Topics: Adamantane; Adult; Aged; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin	2014
Saxagliptin, alone or in combination. No fewer complications; more cases of heart failure? Prescrire international, 2014, Volume: 23, Issue:152 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Heart Failure; Hospitalization; Humans; Risk Assessment; Risk Factors; Treatment Outcome	2014
A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499. Life sciences, 2015, Jan-01, Volume: 120 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3 Cells; Adamantane; Adipocytes; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Design; Enzyme Inhibitors; Glucocorticoids; Haplorhini; Humans; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Sulfonamides; Treatment Outcome	2015
Incretin therapy and beta cell function. Metabolism: clinical and experimental, 2015, Volume: 64, Issue:2 Topics: Adamantane; Animals; Apoptosis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Endoplasmic Reticulum Stress; Insulin-Secreting Cells; Male; Nitriles; Pyrrolidines; Vildagliptin	2015
Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. Advances in therapy, 2014, Volume: 31, Issue:12 Topics: Adamantane; Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Logistic Models; Long-Term Care; Male; Medicare; Medication Adherence; Middle Aged; Proportional Hazards Models; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; United States	2014
Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:6 Topics: Adamantane; Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin	2015
The Yin and the Yang of CV risks in patients with diabetes. The American journal of managed care, 2014, Volume: 20, Issue:8 Spec No. Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration	2014
Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study. Current medical research and opinion, 2015, Volume: 31, Issue:4 Topics: Adamantane; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Monitoring; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Turkey; Vildagliptin	2015
Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes? Diabetes care, 2015, Volume: 38, Issue:3 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Female; Glucosides; Humans; Male; Metformin	2015
Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study. Vascular health and risk management, 2015, Volume: 11 Topics: Adamantane; Adult; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Logistic Models; Male; Middle Aged; Middle East; Nitriles; Odds Ratio; Prevalence; Pyrrolidines; Time Factors; Treatment Outcome; Vildagliptin	2015
Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes. Endocrine, metabolic & immune disorders drug targets, 2015, Volume: 15, Issue:3 Topics: Adamantane; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Treatment Outcome; Vildagliptin	2015
Comparison of hypoglycaemia episodes in people with type-2 diabetes fasting in Ramazan, treated with vildaglipton or sulphonylurea: results of the Pakistani cohort of the VIRTUE study. JPMA. The Journal of the Pakistan Medical Association, 2014, Volume: 64, Issue:11 Topics: Adamantane; Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Middle Aged; Nitriles; Pakistan; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin	2014
[Safety and efficacy of Vildagliptin in real life Chilean diabetic patients]. Revista medica de Chile, 2015, Volume: 143, Issue:1 Topics: Adamantane; Adult; Aged; Aged, 80 and over; Body Mass Index; Chile; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Vildagliptin	2015
Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. BMC pharmacology & toxicology, 2015, Apr-02, Volume: 16 Topics: Adamantane; Administration, Oral; Adolescent; Adult; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Practice Patterns, Physicians'; United Kingdom; United States; Young Adult	2015
ACP Journal Club: in type 2 diabetes, saxagliptin increased HF hospitalizations, regardless of history of HF or CKD. Annals of internal medicine, 2015, Apr-21, Volume: 162, Issue:8 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Female; Heart Failure; Humans; Male	2015
Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus. Journal of diabetes, 2016, Volume: 8, Issue:3 Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Asia; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Young Adult	2016
Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China. Journal of medical economics, 2015, Volume: 18, Issue:10 Topics: Adamantane; Body Mass Index; Cardiovascular Diseases; China; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Female; Hospital Costs; Humans; Hypoglycemia; Hypoglycemic Agents; Insurance Claim Review; Kidney Diseases; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Sulfonylurea Compounds	2015
Comment on Udell et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705. Diabetes care, 2015, Volume: 38, Issue:6 Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Female; Humans; Male; Renal Insufficiency	2015
Regulation of Pancreatic β Cell Mass by Cross-Interaction between CCAAT Enhancer Binding Protein β Induced by Endoplasmic Reticulum Stress and AMP-Activated Protein Kinase Activity. PloS one, 2015, Volume: 10, Issue:6 Topics: Adamantane; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; CCAAT-Enhancer-Binding Protein-beta; Cell Line; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; Gene Expression Regulation; Glucose Tolerance Test; Hypoglycemic Agents; Insulin-Secreting Cells; Islets of Langerhans; Metformin; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nitriles; Phosphorylation; Pyrrolidines; Ribonucleotides; Vildagliptin	2015
Baseline differences in the SAVOR trial. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:12 Topics: Adamantane; Biomedical Research; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Randomized Controlled Trials as Topic; Research Design; Risk; Selection Bias; United States; United States Food and Drug Administration	2015
DPP-4 Inhibitor Reduces Central Blood Pressure in a Diabetic and Hypertensive Patient: A Case Report. Medicine, 2015, Volume: 94, Issue:27 Topics: Adamantane; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypertension; Hypoglycemic Agents; Middle Aged; Nitriles; Pyrrolidines; Vascular Stiffness; Vildagliptin	2015
Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database. Vascular health and risk management, 2015, Volume: 11 Topics: Adamantane; Aged; Aged, 80 and over; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Emergency Service, Hospital; Female; France; Hospitalization; Humans; Hypoglycemia; Insurance, Health; Male; Middle Aged; Nitriles; Pyrrolidines; Regression Analysis; Sulfonylurea Compounds; Vildagliptin	2015
Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats. Cardiovascular diabetology, 2015, Aug-11, Volume: 14 Topics: Adamantane; Animals; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Chloroquine; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Administration Schedule; Injections, Subcutaneous; Male; Microtubule-Associated Proteins; Myocardial Infarction; Myocardium; Nitriles; Proto-Oncogene Proteins c-bcl-2; Pyrrolidines; Rats, Inbred OLETF; Signal Transduction; Time Factors; Ventricular Function, Left; Vildagliptin	2015
Letter by Muskiet et al Regarding Article, "Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". Circulation, 2015, Aug-11, Volume: 132, Issue:6 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Female; Heart Failure; Humans; Male	2015
Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". Circulation, 2015, Aug-11, Volume: 132, Issue:6 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Female; Heart Failure; Humans; Male	2015
Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus. Drug design, development and therapy, 2015, Volume: 9 Topics: Adamantane; Adult; Apelin; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Time Factors; Treatment Outcome; Up-Regulation; Vildagliptin	2015
Response to: 'Baseline differences in SAVOR trial'-- prespecified vs. post hoc analysis--a potential source of bias. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:12 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans	2015
Dipeptidyl peptidase-4 inhibitors and the ischemic heart: Additional benefits beyond glycemic control. International journal of cardiology, 2016, Jan-01, Volume: 202 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Ischemia; Nitriles; Obesity; Oxidative Stress; Pyrrolidines; Rats; Sitagliptin Phosphate; Ventricular Function, Left; Vildagliptin	2016
Saxagliptin prevents vascular remodeling and oxidative stress in db/db mice. Role of endothelial nitric oxide synthase uncoupling and cyclooxygenase. Vascular pharmacology, 2016, Volume: 76 Topics: Adamantane; Animals; Bridged Bicyclo Compounds, Heterocyclic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptides; Endothelium, Vascular; Fatty Acids, Unsaturated; Hydrazines; Male; Mesenteric Arteries; Mice; Mice, Inbred C57BL; NADPH Oxidases; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Pyrazoles; Vascular Remodeling; Vasodilation	2016
Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study. Journal of diabetes, 2016, Volume: 8, Issue:6 Topics: Adamantane; Adult; Aged; Aged, 80 and over; Blood Glucose; China; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Young Adult	2016
Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors. Advances in therapy, 2016, Volume: 33, Issue:1 Topics: Adamantane; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Health Expenditures; Humans; Hypoglycemic Agents; Male; Middle Aged; Retrospective Studies; Sitagliptin Phosphate; United States	2016
Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study. Diabetes care, 2016, Volume: 39, Issue:5 Topics: Adamantane; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome	2016
Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients? Vascular health and risk management, 2016, Volume: 12 Topics: Adamantane; Aged; Asian People; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Female; Glycated Hemoglobin; Health Status Disparities; Humans; Japan; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Treatment Outcome; Vildagliptin; White People	2016
Development and validation of a cyclodextrin-modified capillary electrophoresis method for the enantiomeric separation of vildagliptin enantiomers. Electrophoresis, 2016, Volume: 37, Issue:10 Topics: Adamantane; Cyclodextrins; Diabetes Mellitus, Type 2; Electrophoresis, Capillary; Hydrogen-Ion Concentration; Hypoglycemic Agents; Limit of Detection; Nitriles; Pyrrolidines; Reproducibility of Results; Stereoisomerism; Temperature; Vildagliptin	2016
No heart risk--or benefit--from diabetes drug Onglyza. Harvard heart letter : from Harvard Medical School, 2013, Volume: 24, Issue:4 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Risk	2013
A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2016, Volume: 26, Issue:5 Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2016
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2016, Volume: 26, Issue:5 Topics: Adamantane; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Europe; Female; Heart Failure; Humans; Japan; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration; Young Adult	2016
Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study. Annals of internal medicine, 2016, Jun-07, Volume: 164, Issue:11 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pioglitazone; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones	2016
Urinary metabolomic profiling in mice with diet-induced obesity and type 2 diabetes mellitus after treatment with metformin, vildagliptin and their combination. Molecular and cellular endocrinology, 2016, 08-15, Volume: 431 Topics: Adamantane; Animals; beta-Alanine; Diabetes Mellitus, Type 2; Diet; Glucose Tolerance Test; Hypoglycemic Agents; Male; Metabolomics; Metformin; Mice; Mice, Inbred C57BL; Nitriles; Obesity; Pyridones; Pyrrolidines; Vildagliptin	2016
Switching from subcutaneous insulin injection to oral vildagliptin administration in hemodialysis patients with type 2 diabetes: a pilot study. International urology and nephrology, 2016, Volume: 48, Issue:8 Topics: Adamantane; Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Substitution; Feasibility Studies; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Insulin; Male; Middle Aged; Nitriles; Patient Safety; Patient Selection; Pilot Projects; Pyrrolidines; Renal Dialysis; ROC Curve; Treatment Outcome; Vildagliptin	2016
Low-carbohydrate diet combined with SGLT2 inhibitor for refractory hyperglycemia caused by insulin antibodies. Diabetes research and clinical practice, 2016, Volume: 116 Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Antibodies; Insulin Resistance; Male; Metformin; Nitriles; Pyrrolidines; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin	2016
Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study. Primary care diabetes, 2016, Volume: 10, Issue:6 Topics: Adamantane; Administration, Oral; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; India; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nitriles; Odds Ratio; Prospective Studies; Pyrrolidines; Risk Factors; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Vildagliptin; Weight Gain	2016
Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy. Nutrition & diabetes, 2016, 07-04, Volume: 6, Issue:7 Topics: Adamantane; Adult; Age Factors; Aged; Asia, Eastern; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Latin America; Male; Metformin; Middle Aged; Middle East; Nitriles; Pyrrolidines; Sex Factors; Treatment Outcome; Vildagliptin	2016
Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS. Diabetes care, 2016, Volume: 39 Suppl 2 Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Hypoglycemic Agents; Piperidines; Risk Factors; Sitagliptin Phosphate; Uracil	2016
A case of bullous pemphigoid ınduced by vildagliptin. Cutaneous and ocular toxicology, 2017, Volume: 36, Issue:2 Topics: Adamantane; Administration, Cutaneous; Clobetasol; Complement C3; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Eruptions; Female; Fluorescent Antibody Technique; Gliclazide; Glucocorticoids; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Nitriles; Pemphigoid, Bullous; Pyrrolidines; Skin; Vildagliptin; Withholding Treatment	2017
Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice. Clinical therapeutics, 2016, Volume: 38, Issue:8 Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; General Practice; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Nitriles; Piperidines; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Uracil; Vildagliptin	2016
Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis. Medicine, 2016, Volume: 95, Issue:32 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Kidney Failure, Chronic; Linagliptin; Lipids; Male; Middle Aged; Nitriles; Peritoneal Dialysis; Pyrrolidines; Renal Dialysis; Retrospective Studies; Sitagliptin Phosphate; Treatment Outcome; Vildagliptin	2016
Vildagliptin-induced acute lung injury: a case report. Journal of medical case reports, 2016, Aug-12, Volume: 10, Issue:1 Topics: Acute Lung Injury; Adamantane; Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin	2016
Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats. Drug development research, 2016, Volume: 77, Issue:6 Topics: Adamantane; Animals; Blood Glucose; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hypoglycemic Agents; Inflammation; Insulin; Kidney; Liver; Male; Nitriles; Oxidative Stress; Pancreas; Pioglitazone; Pyrrolidines; Rats; Rats, Wistar; Thiazolidinediones; Urea; Vildagliptin	2016
Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:12 Topics: Acinar Cells; Adamantane; Adenocarcinoma; Adult; Aged; Carcinoma in Situ; Case-Control Studies; Cystadenoma; Diabetes Mellitus, Type 2; Digestive System Surgical Procedures; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Secreting Cells; Humans; Incretins; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Middle Aged; Neuroendocrine Tumors; Nitriles; Organ Size; Pancreas; Pancreas, Exocrine; Pancreatic Neoplasms; Pancreatitis, Chronic; Peptides; Pyrrolidines; Sitagliptin Phosphate; Tissue Donors; Venoms; Vildagliptin	2016
Blood pressure and fasting lipid changes after 24 weeks' treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus. Vascular health and risk management, 2016, Volume: 12 Topics: Adamantane; Biomarkers; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Humans; Linear Models; Lipids; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Treatment Outcome; Vildagliptin; Weight Loss	2016
New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun. Revista espanola de cardiologia (English ed.), 2016, Volume: 69, Issue:11 Topics: Adamantane; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Piperidines; Risk; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Uracil	2016
The effect of vildagliptin relative to sulfonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study. Current medical research and opinion, 2017, Volume: 33, Issue:1 Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Islam; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin	2017
Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies. Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:3 Topics: Adamantane; Adult; Aged; Asian People; Blood Glucose; China; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Ethnicity; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Insulin; Japan; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Racial Groups; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; White People	2017
Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats. PloS one, 2016, Volume: 11, Issue:12 Topics: Adamantane; Animals; Biomarkers; Bone Density; Bone Resorption; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Male; Nitriles; Pioglitazone; Pyrrolidines; Rats; Rats, Zucker; Tartrate-Resistant Acid Phosphatase; Thiazolidinediones; Vildagliptin	2016
Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study. Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:7 Topics: Activities of Daily Living; Adamantane; Aged; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemia; Male; Meals; Middle Aged; Patient Compliance; Precision Medicine; Randomized Controlled Trials as Topic; Recurrence; Self Report; Severity of Illness Index	2017
Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. PloS one, 2017, Volume: 12, Issue:2 Topics: Adamantane; Adult; Aged; Biomarkers, Pharmacological; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Health Status Indicators; Humans; Linagliptin; Male; Middle Aged; Nitriles; Predictive Value of Tests; Prognosis; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Treatment Outcome; Vildagliptin	2017
Effects of Vildagliptin and Metformin on Blood Pressure and Heart Rate Responses to Small Intestinal Glucose in Type 2 Diabetes. Diabetes care, 2017, Volume: 40, Issue:5 Topics: Adamantane; Aged; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucose; Heart Rate; Humans; Hypoglycemic Agents; Intestine, Small; Male; Metformin; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin	2017
Trigonelline and vildagliptin antidiabetic effect: improvement of insulin signalling pathway. The Journal of pharmacy and pharmacology, 2017, Volume: 69, Issue:7 Topics: Adamantane; Alkaloids; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipids; Male; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Receptor, Insulin; Signal Transduction; Vildagliptin	2017
Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study. Current medical research and opinion, 2017, Volume: 33, Issue:5 Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Monitoring; Drug Therapy, Combination; Egypt; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin	2017
Three new drugs for type 2 diabetes. Drug and therapeutics bulletin, 2008, Volume: 46, Issue:7 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin	2008
Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl] The Journal of pharmacology and experimental therapeutics, 2008, Volume: 327, Issue:3 Topics: Adamantane; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Drug Therapy, Combination; Fibrosis; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Mice; Pyrrolidines; Reactive Oxygen Species; Tetrazoles; Valine; Valsartan	2008
Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Current drug targets, 2009, Volume: 10, Issue:1 Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drugs, Investigational; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Treatment Outcome; Triazoles; Vildagliptin	2009
Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:6 Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Nitriles; Pyrrolidines; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vildagliptin; Weight Gain	2009
Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes. Diabetes, obesity & metabolism, 2009, Volume: 11 Suppl 2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Vildagliptin	2009
[Vildagliptin (Galvus) and fixed combination vildagliptine-metformin (Eucreas) in the treatment of type 2 diabetes]. Revue medicale de Liege, 2009, Volume: 64, Issue:3 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin	2009
Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes. Prescrire international, 2008, Volume: 17, Issue:97 Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Combinations; Europe; Humans; Metformin; Nitriles; Pyrrolidines	2008
Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. International journal of clinical practice, 2009, Volume: 63, Issue:10 Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin	2009
FDA approves saxagliptin for type 2 diabetes. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2009, Sep-01, Volume: 66, Issue:17 Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Humans; Hypoglycemic Agents; United States; United States Food and Drug Administration	2009
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:4 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2009
Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon. Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:8 Topics: Adamantane; Cinnamomum zeylanicum; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles	2009
Saxagliptin (Onglyza) for type 2 diabetes. The Medical letter on drugs and therapeutics, 2009, Nov-02, Volume: 51, Issue:1324 Topics: Adamantane; Administration, Oral; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Drug Interactions; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Treatment Outcome	2009
Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus. Regulatory peptides, 2010, Feb-25, Volume: 160, Issue:1-3 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gerbillinae; Glucagon-Like Peptide 1; Immunohistochemistry; Insulin; Liraglutide; Male; Nitriles; Pancreas; Pyrrolidines; Reference Standards; Vildagliptin	2010
Saxagliptin in type 2 diabetes. Drugs of today (Barcelona, Spain : 1998), 2010, Volume: 46, Issue:2 Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Hypoglycemic Agents; Medication Adherence	2010
[New hypoglycemic agents in type 2 diabetes]. La Revue du praticien, 2010, Apr-20, Volume: 60, Issue:4 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2010
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:6 Topics: Adamantane; Aged; Clinical Trials as Topic; Confidence Intervals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Immune System; Liver; Male; Nitriles; Pancreas; Pyrrolidines; Risk Factors; Skin; Vildagliptin	2010
Choosing among the incretin agents and why it matters. The Journal of family practice, 2010, Volume: 59, Issue:5 Suppl Topics: Adamantane; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Lipids; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss	2010
Saxagliptin efficacy. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:8 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Postprandial Period; Treatment Outcome	2010
Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study. Diabetes research and clinical practice, 2010, Volume: 90, Issue:2 Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Drug Tolerance; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney Function Tests; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Safety; Thiazolidinediones; Vildagliptin	2010
Multidrug therapy in a patient with Rabson-Mendenhall syndrome. Diabetologia, 2010, Volume: 53, Issue:11 Topics: Adamantane; Adolescent; Diabetes Mellitus, Type 2; Donohue Syndrome; Humans; Hypoglycemic Agents; Male; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Vildagliptin	2010
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2010
Distinguishing among incretin-based therapies. Patient education and self-management. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms	2010
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss	2010
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms	2010
Distinguishing among incretin-based therapies. Introduction. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2010
[Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2010, Volume: 136, Issue:5 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose Intolerance; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Islets of Langerhans; Nitriles; Pyrrolidines; Vildagliptin	2010
[Saxagliptin (Onglyza): new inhibitor of the dipeptidylpeptidase-4 for the oral treatment of type 2 diabetes]. Revue medicale de Liege, 2010, Volume: 65, Issue:9 Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans	2010
Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:1 Topics: Adamantane; Aged; Aged, 80 and over; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Nitriles; Polypharmacy; Pyrrolidines; Treatment Outcome; Vildagliptin	2011
Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension. European journal of pharmacology, 2011, Mar-01, Volume: 654, Issue:1 Topics: Adamantane; Administration, Oral; Animals; Aorta; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Endothelium, Vascular; Epoxide Hydrolases; Hypertension; Male; Mesenteric Arteries; Mice; Mice, Inbred C57BL; Niacinamide; Obesity; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Urea; Vasodilation	2011
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development. Contemporary clinical trials, 2011, Volume: 32, Issue:3 Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin	2011
Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacological research, 2011, Volume: 63, Issue:5 Topics: Adamantane; Animals; Aorta, Thoracic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycation End Products, Advanced; Male; Nitriles; Obesity; Pyrrolidines; Rats; Rats, Inbred OLETF; Vascular System Injuries; Vildagliptin	2011
Understanding the incretin effect. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:4 Topics: Adamantane; Animals; Blood Glucose; Comprehension; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Incretins; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Vildagliptin	2011
Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions. Prescrire international, 2011, Volume: 20, Issue:113 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Interactions; European Union; Humans; Hypoglycemic Agents	2011
Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Current medical research and opinion, 2011, Volume: 27, Issue:7 Topics: Adamantane; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Gliclazide; Humans; Hypoglycemic Agents; Islam; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Time Factors; Vildagliptin	2011
Effectiveness of adding vildagliptin to the treatment of diabetic patients nonresponsive to the combination of metformin and a sulphonylurea. Arquivos brasileiros de endocrinologia e metabologia, 2011, Volume: 55, Issue:4 Topics: Adamantane; Administration, Oral; Adult; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Time Factors; Treatment Failure; Treatment Outcome; Vildagliptin	2011
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Clinical drug investigation, 2011, Volume: 31, Issue:9 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin	2011
Place in therapy for liraglutide and saxagliptin for type 2 diabetes and FDA liraglutide warning. Southern medical journal, 2011, Volume: 104, Issue:8 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Incretins	2011
Design, synthesis, and SAR studies of novel polycyclic acids as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1). Bioorganic & medicinal chemistry letters, 2011, Nov-15, Volume: 21, Issue:22 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Acetic Acid; Acids; Adamantane; Diabetes Mellitus, Type 2; Drug Design; Enzyme Inhibitors; Humans; Models, Molecular; Protein Binding; Structure-Activity Relationship	2011
The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland. Diabetes technology & therapeutics, 2012, Volume: 14, Issue:1 Topics: Adamantane; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin, Isophane; Male; Metformin; Middle Aged; Models, Economic; Poland; Quality-Adjusted Life Years; Sulfonylurea Compounds	2012
Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis. Clinical drug investigation, 2012, Mar-01, Volume: 32, Issue:3 Topics: Adamantane; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality-Adjusted Life Years	2012
Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metfo Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:4 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines	2012
The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice. Experimental diabetes research, 2012, Volume: 2012 Topics: Adamantane; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Apoptosis; Blood Glucose; Diabetes Mellitus, Type 2; Drug Synergism; Endothelial Cells; Endothelium, Vascular; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Inflammation; Intercellular Adhesion Molecule-1; Mice; NADPH Oxidases; Oxidative Stress; Pyrrolidines; Receptors, Glucagon; Tetrazoles; Valine; Valsartan; Vascular Cell Adhesion Molecule-1	2012
Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:10 Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptides; Drinking; Eating; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Immunohistochemistry; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Pyrazines; Sitagliptin Phosphate; Triazoles	2012
Emerging role of DPP-4 inhibitor Vildagliptin in the management of type-2 diabetes. The Journal of the Association of Physicians of India, 2011, Volume: 59 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Nitriles; Pyrrolidines	2011
[Therapeutic use and adverse events of incretin-related drugs]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 3 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin	2012
Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats. European journal of pharmacology, 2012, Sep-15, Volume: 691, Issue:1-3 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adamantane; Animals; Apoptosis; Cell Proliferation; Deoxyguanosine; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Eating; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Nitriles; Pyrrolidines; Rats; Time Factors; Vildagliptin	2012
Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats. American journal of physiology. Heart and circulatory physiology, 2012, Oct-01, Volume: 303, Issue:7 Topics: Adamantane; Animals; Blood Glucose; Blotting, Western; Calcium Signaling; Crosses, Genetic; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Eicosanoids; Enzyme Inhibitors; Epoxide Hydrolases; Heart Diseases; Hypoglycemic Agents; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Mitochondria, Heart; Myocytes, Cardiac; Myofibrils; Rats; Rats, Sprague-Dawley; Rats, Zucker; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Time Factors; Urea	2012
Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS. Bioanalysis, 2012, Volume: 4, Issue:15 Topics: Adamantane; Administration, Oral; Biological Availability; Calibration; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation; Humans; Injections, Intravenous; Male; Mass Spectrometry; Reproducibility of Results; Sensitivity and Specificity	2012
Factors associated with the glucose-lowering effect of vildagliptin identified from the results of the oral glucose tolerance test in Japanese patients with type 2 diabetes. Endocrine journal, 2013, Volume: 60, Issue:1 Topics: Adamantane; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Japan; Male; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin	2013
A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. European journal of pharmacology, 2012, Dec-05, Volume: 696, Issue:1-3 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Nitriles; Pyrazines; Pyrazoles; Pyrrolidines; Rats; Rats, Wistar; Rats, Zucker; Sitagliptin Phosphate; Thiazolidines; Triazoles; Vildagliptin	2012
Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory Activity. PloS one, 2012, Volume: 7, Issue:10 Topics: Acetylcholine; Adamantane; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Blood Pressure; Blotting, Western; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; E-Selectin; Egg Proteins; Endothelium, Vascular; Immunohistochemistry; In Vitro Techniques; Kidney; Nitriles; Peptidyl-Dipeptidase A; Prostaglandin-Endoperoxide Synthases; Protein Hydrolysates; Pyrrolidines; Rats; Rats, Inbred SHR; Rats, Zucker; Reverse Transcriptase Polymerase Chain Reaction; Vasodilation; Vasodilator Agents; Vildagliptin	2012
Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease. Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:21 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucagon-Like Peptide 1; Humans; Incretins; Kidney Failure, Chronic; Liraglutide; Magnetic Resonance Imaging; Male; Nitriles; Pancreatitis; Pyrrolidines; Renal Dialysis; Tomography, X-Ray Computed; Vildagliptin	2012
Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease. Diabetes care, 2013, Volume: 36, Issue:6 Topics: Adamantane; Aged; Carbamates; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Ischemic Preconditioning; Male; Middle Aged; Nitriles; Piperidines; Prospective Studies; Pyrrolidines; Vildagliptin	2013
Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082. Diabetes care, 2013, Volume: 36, Issue:1 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Nitriles; Pyrazines; Pyrrolidines; Triazoles	2013
Response to Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082. Diabetes care, 2013, Volume: 36, Issue:1 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Nitriles; Pyrazines; Pyrrolidines; Triazoles	2013
Acute necrotizing pancreatitis associated with vildagliptin. JOP : Journal of the pancreas, 2013, Jan-10, Volume: 14, Issue:1 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Male; Middle Aged; Nitriles; Pancreatitis, Acute Necrotizing; Pyrrolidines; Vildagliptin	2013
Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect? Diabetic medicine : a journal of the British Diabetic Association, 2013, Volume: 30, Issue:4 Topics: Adamantane; Aged; Angioedema; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Substitution; Humans; Male; Nitriles; Piperidines; Pyrrolidines; Uracil; Vildagliptin	2013
Saxagliptin and tuberculosis. Prescrire international, 2013, Volume: 22, Issue:134 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Risk Factors; Tuberculosis	2013
Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2014, Volume: 15, Issue:4 Topics: Adamantane; Albuminuria; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diastole; Drug Therapy, Combination; Fasting; Hypoglycemic Agents; Male; Nitriles; Pyrrolidines; Rats, Wistar; Systole; Telmisartan; Vildagliptin	2014
1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. Journal of medicinal chemistry, 2003, Jun-19, Volume: 46, Issue:13 Topics: Adamantane; Administration, Oral; Animals; Biological Availability; Blood Glucose; Caco-2 Cells; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Macaca fascicularis; Male; Pyrrolidines; Rats; Rats, Zucker; Structure-Activity Relationship	2003
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Journal of medicinal chemistry, 2005, Jul-28, Volume: 48, Issue:15 Topics: Adamantane; Animals; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Glucose Tolerance Test; Glycine; Humans; Hypoglycemic Agents; In Vitro Techniques; Insulin; Male; Mice; Mice, Obese; Microsomes, Liver; Nitriles; Proline; Protease Inhibitors; Rats; Rats, Zucker; Stereoisomerism; Structure-Activity Relationship	2005
7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity. The Journal of pharmacology and experimental therapeutics, 2006, Volume: 319, Issue:3 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Dose-Response Relationship, Drug; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Tolerance Test; Hypoglycemic Agents; Imidazoles; Insulin; Kinetics; Mice; Mice, Inbred C57BL; Nitriles; Piperazines; Protease Inhibitors; Purines; Pyridazines; Pyrrolidines; Rats; Rats, Zucker; Tosyl Compounds; Vildagliptin	2006
Oral agents for type 2 diabetes reduce HbA1c, are weight neutral. Geriatrics, 2006, Volume: 61, Issue:9 Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes. Bioorganic & medicinal chemistry letters, 2007, Mar-01, Volume: 17, Issue:5 Topics: Adamantane; Adenosine Deaminase Inhibitors; Amides; Aniline Compounds; Animals; Benzylamines; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Inhibitory Concentration 50; Nitriles; Phenethylamines; Pyrrolidines; Rats; Rats, Wistar; Structure-Activity Relationship; Vildagliptin	2007
Gliptins. Lancet (London, England), 2007, Jan-27, Volume: 369, Issue:9558 Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Neuropeptide Y; Nitriles; Pyrrolidines; Vildagliptin	2007
New treatments for diabetes. The New England journal of medicine, 2007, May-24, Volume: 356, Issue:21 Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glipizide; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin	2007
Which patients are candidates for dipeptidyl peptidase IV inhibitors? American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Volume: 64, Issue:12 Topics: Adamantane; Ambulatory Care; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Humans; Nitriles; Pyrrolidines; Vildagliptin	2007
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes]. Revue medicale de Liege, 2007, Volume: 62, Issue:4 Topics: Adamantane; Animals; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
[Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic]. Lakartidningen, 2007, Dec-05, Volume: 104, Issue:49-50 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Nitriles; Peptides; Pyrrolidines; Receptors, Glucagon; Treatment Outcome; Venoms; Vildagliptin	2007
Islet cell function is as interesting as insulin resistance for T2DM treatment options. International journal of clinical practice. Supplement, 2008, Issue:159 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Insulin Resistance; Islets of Langerhans; Nitriles; Pyrrolidines; Vildagliptin	2008
2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice. Journal of medicinal chemistry, 2008, May-22, Volume: 51, Issue:10 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Adipose Tissue; Animals; Cortisone; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Humans; Hydrocortisone; Hypoglycemic Agents; Ligands; Liver; Male; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Rats; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Triazoles	2008
Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:11 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidases; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Female; Humans; Male; Mice; Mice, Inbred Strains; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Recombinant Proteins; Toxicity Tests; Vildagliptin	2008
Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clinical science (London, England : 1979), 2009, Volume: 116, Issue:1 Topics: Adamantane; Animals; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Evaluation, Preclinical; Enzyme Inhibitors; Epoxide Hydrolases; Hypertension; Insulin; Lauric Acids; Lipids; Male; NF-kappa B; Rats; Rats, Inbred Strains	2009